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Abstract 
It is well established that dynamic mechanical loading is both beneficial and necessary to 
the promotion and development of healthy bones. The aim of this study is to determine 
the response of osteokines related to the anabolic Wnt signalling pathway [sclerostin and 
dickkopf 1 (DKK-1)] and the catabolic RANKL pathway, [osteoprotogerin (OPG), 
receptor activator of nuclear factor kappa-β ligand (RANKL)], as well as the related 
transforming growth factors (TGF-β1, TGF-β2 and TGF-β3) to an acute bout of 
plyometric exercise in girls and adolescent females. Twenty six females, 14 girls (10.5 ± 
0.4 years of age) and 12 adolescents (15.0 ± 0.3 years of age) were recruited to participate 
in this study. Serum samples were collected pre, 5 min post, 1 hour post and 24 h post 
exercise. Group differences were seen at baseline in DKK-1, TGF-β1, TGF-β2 and TGF-
β3 with girls having significantly higher concentrations than the adolescents. A 
significant decrease was found after 24 hours in DKK-1. A significant decrease was also 
found in RANKL at 5 minutes post exercise that remained suppressed 1 hour and 24 
hours following the cessation of the exercise protocol in both groups. Plyometric exercise 
was therefore successful in suppressing the catabolic osteokines DKK-1 and RANKL up 
to 24 hours following the cessation of exercise in girls and adolescent females. 
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Chapter 1: Introduction 
1.1 Rationale 
Physical activity is an important factor of bone health, particularly in children. 
Wolff’s Law states that “the form or function of a bone is followed by adaptive changes 
in its internal architecture and its external shape” (1); in a pediatric population, physical 
activity is an important stimulus for this adaptive change. The response of bone to 
physical activity can be measured in a variety of ways. When studying physical activity in 
the acute sense (over hours); common measures are bone biomarkers. These can be in the 
form of direct measures of bone formation or resorption (termed bone turnover markers) 
or indirect indicators of formation or resorption activity (termed osteokines). Mechanical 
loading through physical activity has been shown to influence a variety of osteokines in 
human adult populations. Sclerostin, which is an inhibitor of the anabolic Wnt signalling 
pathway, has been proposed to have a negative linear relationship with physical activity 
(2). Similar to sclerostin, dicckopf-1 (or DKK-1) is an inhibitor of the anabolic Wnt 
signalling pathway. Its response to exercise is unknown. Conversely, the catabolic nuclear 
factor kappa-β ligand (RANKL) pathway is also affected by physical activity with 
RANKL, and its decoy receptor osteoprotegerin (OPG) being stimulated through physical 
activity (3). However, pediatric populations are largely understudied when it comes to 
these anabolic and catabolic osteokines. Therefore, the aim of this research is to address 
this gap in the literature. A window of insight into the effects of physical activity is seen 
in cross-sectional studies examining different types of sports on bone properties in 
children. Children who participate in high impact sports such as artistic gymnastics show 
greater bone mineral density (BMD) than swimmers or recreationally active children (4). 
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The amount of physical activity undertaken daily is also a significant predictor of bone 
health in pediatric populations (5) as well as adult male populations (6). 
Physical activity and its relationship with bone parameters (such as biochemical 
markers of bone turnover) are typically studied in three ways: acutely, in the short term 
(0-6 months), or over a long term (6 months or longer). Typically, short term and long 
term studies are undertaken to determine the effects of an exercise intervention on makers 
of bone turnover independent of bone growth through the use of an intervention group 
and a control group. In children, these interventions tend to be school-based and involve 
plyometric protocols such as jumping, as this type of plyometric training has been shown 
to produce sufficient forces to stimulate a bone response (7,8). Less often, however, are 
the acute effects of a single exercise session examined in relation to markers of bone 
turnover. Even rarer are pediatric studies of the acute response of bone parameters to 
exercise. Physical activity is key to achieving an optimal peak bone mass in late 
adolescence and early adulthood; yet very little research has been done to investigate 
difference types of exercise and their potential to alter bone metabolism.  To date, only 
two studies have examined the effects of acute exercise on bone markers in children. One 
examined cycling in pubertal boys – a mode of exercise that is not considered osteogenic 
– and only measured a few markers of bone turnover (9). The other compared the effects 
of a single session of plyometric training on bone turnover markers in boys and men. 
They demonstrated elevated markers of both formation and resorption in boys but not 
men 24 hours following the exercise session (10) and that sclerostin responded to exercise 
in men but not boys (11).  
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1.2 Objectives and Hypothesis 
The overall purpose of this study was to determine the response of osteokines 
related to the anabolic Wnt signalling [sclerostin and dickkopf 1 (DKK-1)] and the 
catabolic RANKL pathways, [osteoprotegerin (OPG), receptor activator of nuclear factor 
kappa-β ligand (RANKL)], as well as the related transforming growth factors (TGF-β1, 
TGF-β2 and TGF-β3) to an acute bout of plyometric exercise in girls and adolescent 
females. The specific objectives of this study are: (1) To compare the resting serum levels 
of anabolic and catabolic osteokines as well as transforming growth factors between girls 
and adolescents, (2) to determine the acute effects of a single bout of plyometric exercise 
on other markers/osteokines and growth factors associated with the Wnt and RANKL 
pathways over 24 hours in girls and adolescents, and (3) to determine whether there are 
differences in these acute responses between the two groups. A secondary aim of this 
research is to determine whether energy expenditure and dietary intake play a role in 
these responses to a single bout of plyometric exercise.   
It is hypothesized that: (1) resting serum levels of osteokines and growth factors 
will be higher in the girls than the adolescents, (2) osteokines and growth factors will 
increase one hour after exercise and will return to baseline after 24 hours, and (3) girls 
will demonstrate higher levels of all markers than adolescents but both groups will show 
the same pattern of variation in response to the acute protocol.  
Dynamic mechanical loading (such as plyometric exercise) promotes bone 
formation in both children and adults. When the rate of bone turnover is balanced in equal 
rates of formation and resorption, bone mineral density is maintained. When this rate is 
shifted in favour of bone formation, bone mineral density is increased; when shifted in 
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favour if resorption, bone mineral density is decreased. However, the acute anabolic and 
catabolic response of bone metabolism to this plyometric exercise is not fully understood. 
Since acute exercise is capable of stimulating shifts in bone metabolism, it can help us 
better understand the relationship between bone metabolism and exercise. A better 
understanding of the relationship between bone metabolism and exercise is most certainly 
beneficial, if not to aid in achieving optimal peak bone mass, then certainly to aid in 
preventing age-related bone diseases such as osteoporosis. Since the literature on this 
topic is limited in adults and scarce in children, this study will aid in the standardization 
of timing of blood sampling in order to study bone metabolism as well as enable a direct 
comparison of bone metabolism in children and adults. 
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Chapter 2: Review of Literature 
2.1 General Bone Physiology 
2.1.1 Bone Anatomy, Development and Turnover 
Bone can be divided into two components: cortical bone and trabecular bone (also 
known as cancellous bone). Cortical bone is heavily mineralized to provide structural 
support, and is located in the diaphysis or shaft of the long bones (12,13). Trabecular 
bone is calcified to a lesser extent than cortical bone and is found at the epiphyses of long 
bones. Trabecular bone has a greater surface area than cortical bone, which allows it to be 
more metabolically active (12,13).  
Structurally, there are two type of matrices within bone; the organic matrix which 
is comprised of mostly Type I collagen as well as the inorganic or mineral matrix which 
is comprised of mostly calcium and phosphate (1,12,13).  
Within the organic matrix, three types of cells predominate: osteoblasts, 
osteoclasts and osteocytes. Osteoblasts are bone-forming cells that synthesize and 
mineralize the organic matrix. Osteoclasts are bone-resorbing cells that locally degrade 
bone matrix (12). Osteocytes are derived from osteoblasts trapped within the bone matrix 
(12) and account for 90-95% of adult bone cells. Among other possible functions, these 
cells respond to mechanical strain via signals of formation and resorption (14). When 
mechanically loaded, osteocytes recruit osteoblasts to form new bone. The bone 
remodelling cycle begins when osteoclasts on the bone surface are activated; typically in 
response to osteocyte apoptosis and begin to resorb the surface bone matrix (1). The 
deficit left in the bone is then filled by osteoblasts. This entire process takes 
approximately 200 days to complete  in adult populations (13) (see Figure 1).  
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Figure 1. Bone Cells and Bone Turnover. Osteoclasts resorb bone and the bone defect 
is built back slightly stronger than before by the osteoblasts (13). 
 
2.1.2 Wnt Pathway 
The Wnt/β-catenin signalling pathway - also referred to as the canonical Wnt 
pathway or the canonical β-catenin-dependent Wnt signalling pathway is involved in 
determining cell fate, proliferation and survival (15). Wnt signalling is a bone anabolic 
pathway and is an important component of the induction of osteoblastogenesis. Wnt 
signalling promotes the renewal of stem cells, stimulates preosteoblast replication, 
osteoblast differentiation as well as inhibits osteoblast and osteocyte apoptosis (16).  
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Wnts are cysteine-rich secreted glycoproteins that interact with the co-receptor 
complexes low-density lipoprotein receptor 5 (LRP5), low-density lipoprotein receptor 6 
(LRP6) and the frizzled receptor (Fzd) (14,15,17–20). This interaction causes the 
activation of the dishevelled receptor (Dsh) via phosphorylation (14,17) which in turn 
results in the phosphorylation of glycogen synthase kinase-3β (GSK-3β). This causes the 
phosphorylation of β-catenin which accumulates and translocates to the nucleus, where it 
begins to affect gene transcription (14,15,17–19) in favour of bone formation (14–17) 
(see Figure 2).  
 
Figure 2. Wnt Signalling. Cysteine-rich secreted glycoproteins Wnts attach to the low-
density lipoprotein receptor complex 5 and 6 (LRP5 and LRP6) and the frizzled receptor 
(Fzd). This causes the activation of Dsh and GSK-3β which in turn causes β-catenin to 
accumulate. This β-catenin then translocates to the nucleus to affect gene transcription 
(TCF) in favour of bone formation (17).  
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2.2 Biochemical Factors Associated with the Wnt Pathway 
2.2.1 Sclerostin 
The discovery of the protein sclerostin and the identification of its role in bone 
catabolism and turnover resulted in an increased interest in the mechanism by which it 
interacts with other markers of bone metabolism. Sclerostin is an atypical, soluble (21) 
cysteine knot secreted glycoprotein that is expressed by the Sost gene in osteocytes 
(18,19,21–23). Sclerostin has been shown to be secreted primarily within osteocytes 
(19,21,23–29) and to some extent within chondrocytes (26). Osteocytes secreting 
sclerostin are more likely to be buried deep within the bone matrix, rather than at the 
superficial bone surface (21,26–28). 
Sclerostin works as an osteokine to inhibit bone formation through antagonizing 
the canonical Wnt signalling pathway (19,21,22,24,25,27,30–32). By inhibiting the 
actions of LRP5 (2,18,19,21,22,24–27,32,33) and LRP6 (18,19,22,25,27,32,33), 
sclerostin inhibits osteoblastogenesis by preventing the formation of the active LRP 
complex (33) which inhibits the Wnt pathway from allowing bone formation to occur. 
Thus, sclerostin indirectly promotes osteoclast function (34). Sclerostin has demonstrated 
catabolic effects on bone within the animal model in the sense that targeted reductions in 
sclerostin levels lead to increases in bone mass (33).  
Sclerostin is secreted by osteocytes after they become imbedded in the 
mineralized matrix, though the specific mechanism is still unclear (25). This indicates that 
high levels of circulating sclerostin can cause even greater bone loss as osteoclasts 
formed in this environment are more effective at resorbing the bone matrix than pre-
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existing osteoclasts. In an animal model it has been shown that high rates of bone 
formation are present in the absence of sclerostin (35). In human disease states where 
sclerostin is low (such as in menopause), it has been shown that serum sclerostin levels 
are significantly higher in post-menopausal women than their pre-menopausal 
counterparts (36–42). In human disease states, rare gene mutations can lead to 
sclerosteosis or van Buchem disease; both characterized by an inability of the osteocyte to 
transcribe Sost in order to express sclerostin. Both of these diseases present with 
enlargement of facial and mandibular bones and can cause cranial nerve damage and is 
associated with sensory loss (25). Animal models have demonstrated that overexpression 
of sclerostin leads to decreases in BMD of the axial skeleton through the suppression of 
the Wnt pathway as well as blunting the osteogenic response to mechanical loading (43). 
The suppression of sclerostin has been shown to induce bone formation even in the 
absence of prior resorption (32). Through animal models, it has also been shown that 
targeted sclerostin deletion leads to a high accrual of bone mass (33). It has therefore been 
hypothesized that sclerostin antibodies could aid in the reduction of the negative effects 
of sclerostin on bone formation. Early trials have indicated that antibody-based sclerostin 
inhibition increases bone mass through increased bone formation coupled with decreased 
bone resorption (26,33,44). This antibody-based treatment has been suggested as a new 
method of treating bone loss such as the age-related bone loss seen in osteoporosis (21). 
2.2.2 DKK-1 
DKK-1 is a glycoprotein secreted primarily by osteoblasts and osteocytes (45) that 
attaches to the LRP 5/6 receptor complex (46,47) to directly inhibit Wnt signalling (45), 
directly contribute to bone loss (48)  as well as suppress bone formation (49), much like 
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its counterpart sclerostin (46). DKK-1 is therefore another osteokine that directly inhibits 
osteoblast-mediated bone mineralization (45) by preventing osteoblastogenesis and 
promoting programmed cell death (46). In the animal model, expression of DKK-1 is 
limited to bone in adult animals (45), though it can be expressed in endothelial cells 
elsewhere, such as in the cardiovascular system (50). DKK-1 has also been linked to 
osteoclast development in vivo within the animal model (51).  
DKK-1inhibits Wnt-dependent osteoblast differentiation (51,52) as well as Wnt-
induced production of OPG (51) and subsequently increases the expression of RANKL 
(52). Overexpression of DKK-1 has been demonstrated to lead to osteopenia (45), 
however, neither DKK-1 nor sclerostin have been linked to fracture risk in older adults 
(53). Serum levels of DKK-1 may also be involved in glucocorticoid- and estrogen 
deficiency- mediated osteoporosis (46), and negatively associated with bone mineral 
density (52). Serum levels of DKK-1 are higher in post-menopausal women who are 
osteoporotic compared to those who are not osteoporotic (54). 
In the animal models, anti-DKK-1 antibodies have also been shown to have a 
dose-dependent decrease in osteoclast count (48) as wells as a significant increase in new 
bone formation (49). Decreased serum DKK-1 concentrations due to antibody treatment 
are also correlated with increased markers of bone formation such as P1NP and OC as 
well as being correlated to positive measures of bone strength such as increased bone 
mass, improved bone microstructure and decreased bone loss (55). Pharmaceutical 
therapies such as biophosphates are also successful in decreasing DKK-1 levels in post-
menopausal osteoporotic women (54).  
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Figure 3. The Wnt Pathway When sclerostin (Sost) and dicckopf 1 (DKK-1) attach to 
LRP5/6, the entire cascade that allows for gene transcriptions that promote bone 
formation to occur is blocked (26).  
 
2.2.3 TGF-β 
The Transforming growth factor-β (TGF-β) is expressed in cells of the immune 
system as well as in osteoblasts, is also involved in osteoclastogenesis along with 
osteoclast regeneration (56) and osteoblasts have high concentrations of TGF-β receptors 
(57). There are three different isoforms of TGF-β: TGF-β1, TGF-β2 and TGF-β3. TGF-
β1 is found largely in superficial, transitional or immature bone cells and is the first to 
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respond to bone fracture through either secretion by platelets or synthesis from osteocytes 
(57). The isoforms of TGF-β1 and TGF-β2 are structurally very similar, however their 
concentration and actions are quite different. TGF-β1 concentration in bone is 4 times 
greater than that of TGF-β2; yet the action of TGF-β2 is 3.75-fold higher than that of 
TGF-β1 (57). TGF-β2 responds more transiently than TGF-β1 and is present once TGF-
β1 have decreased while TGF-β3 concentrations and activity remain largely stable over 
time (57), although the greatest effect of TGF-β3 on bone formation is seen in a longer 
time frame (20-30 days) (58). 
TGF-β can influence bone formation independently of the Wnt pathway, and/or it 
can interact with the Wnt pathway (TGF-β1 in particular) to block DKK-1 (59), and 
therefore, can prevent inhibition of Wnt signalling. Independent from the Wnt pathway, 
TGF-β2 has been shown to induce the corticalization and mineralization of bone tissue 
(60). TGF-β3 appears to be the most direct contributor to bone formation as it is capable 
of inducing significant osteogenesis through the upregulation of osteocalcin (or OC, a 
potent bone formation marker), as wells as influencing the differentiation of stem cells 
into an osteoblastic lineage (61). Aside from bone formation during growth or healing 
from fracture, all TGF-β isoforms found in mammals are involved in the ossification of 
non-bone tissues (62), in particular TGF-β1 (63) and TGF-β2 (62).  
It has also been suggested that TGF-β can directly influence the Wnt signalling 
pathway by preventing phosphate-induced transcription factors, essential to bone 
formation, from translocating to the nucleus of the osteocyte – namely β-catenin (64). 
When interacting with the Wnt pathway, TGF-β  is released from osteoclasts and 
activated during bone resorption (56) and works to increase bone resorption through 
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altering the OPG:RANKL ratio (65). TGF-β  is another marker of the anabolic response 
to bone and it has be demonstrated that the repression of TGF-β via mechanical loading is 
another important regulator of sclerostin (66). The presence of TGF-β induces the 
expression of sclerostin (67,68) and exerts its effects on bone metabolism independently 
of PTH-mediated pathways (67); however, this effect may be greater in the animal model 
than in the human model, as TGF-β has been found to have negligible effects on 
sclerostin expression in human cell lines (69) when compared to animal cell lines. The 
animal model also suggests that increased concentrations of TGF-β in turn result in 
increased concentrations of DKK-1 (64).  
2.2.4 OPG/RANKL 
Nuclear factor kappa-β ligand (RANKL) is secreted by many tissues including the 
osteoclast and is a marker of bone resorption that is necessary for osteoclast function 
(32,70) through promoting complete differentiation of osteoclast precursors into mature 
osteocytes (71) as well as the induction of osteoclast activation (72). When RANKL binds 
to its associated receptor RANK on osteoclast precursors, it allows osteoclast 
differentiation and function to be enhanced (73,74). RANKL stimulates the fusion of 
osteoclasts to bone and subsequently promotes their activation and survival (70,74) as 
well as promoting osteocyte apoptosis (32).  
Osteoprotegerin (OPG) is a decoy for RANKL (32,70,73,74) that is secreted by 
osteoblasts (73,74) to prevent osteoclast differentiation and activity (71) and accelerate 
osteoclast apoptosis (70,72) namely through preventing the actions of nuclear factor 
kappa-β ligand (RANKL) (71,72). Increases in levels of OPG have been associated with 
decreased osteoclast number as well as increased bone strength and bone density in the 
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animal model (70). Uninhibited Wnt signalling stimulates the production and secretion of 
OPG, thereby antagonizing RANKL and decreasing osteoclast differentiation (20). 
The ratio of OPG to RANKL is a critical regulator of osteoclast function and bone 
resorption (73). RANKL is a marker of bone resorption. Although increased levels of 
RANKL are associated with increased bone resorption (32,70), the presence of RANKL 
alone is insufficient to stimulate resorption independently (70). In order for resorption to 
be mediated by RANKL, there needs to be an associated decrease in OPG (70).  
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Figure 4. Osteokines and Growth Factors Related to the Wnt Pathway. Both 
sclerostin and DKK-1 inhibit the Wnt signalling pathway in the osteocyte to prevent β-
catenin from translocating to the nucleus, decreasing the transcription of markers such as 
OPG, leading to an increase in RANKL. TGF-β directly prevents β-catenin from 
translocating to the nucleus as well as increasing transcription of sclerostin and DKK-1 to 
inhibit the Wnt pathway.  
 
2.2.5 Across the Lifespan 
2.2.5.1 Children and Adolescents 
The role of osteokines such as sclerostin and DKK-1 in human bone development 
in athletic and non-athletic pediatric populations has been largely understudied. Early 
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investigations indicate that serum sclerostin is higher in pre-pubertal boys than pre-
pubertal girls (75), and higher in pediatric weight-bearing athletes compared with non-
athletes (76). In a healthy pediatric population, whether recreationally active or weight-
bearing athletes, there appears to be no linear relationship between classical bone 
parameters such as bone turnover or BMD and serum sclerostin (75,76). However, the 
presence of a “split point” or non-linear relationship between sclerostin and chronological 
age has been postulated. It has been shown that before the age of 10 years in girls and 14 
years in boys, there is a positive association between sclerostin and bone age, and after 
this split point, there is a negative  association between sclerostin and bone age (75). This 
indicates the potential of a maturational effect of sclerostin levels, and therefore could 
offer a window of opportunity to promote bone development. 
When it comes to levels of OPG and RANKL in children, it would appear there is 
also no relationship between either marker, nor the ratio of the two, on BMD in 
adolescent females (77). When approaching sexual maturity, serum concentrations of 
OPG steadily increase, and continue to increase after sexual maturity, whereas RANKL 
steadily decreases while approaching sexual maturity and continues to decrease after 
sexual maturity has been reached (77). There is no difference in levels of RANKL 
between obese and normal weight children, however serum levels of OPG in obese 
children are decreased compared to their normal weight counterparts. OPG is also 
correlated with trunk and total fat mass in children whereas RANKL is not (78). 
Neither TGF-β nor DKK-1 have been studied in healthy pediatric populations. 
DKK-1 is not associated with total fat mass in either obese children or normal weight 
controls (78). TGF-β is largely studied in disease states, such as Marfan Syndrome (79). 
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Our study will be one of the first to address this gap in the literature. Since literature 
regarding these two markers in healthy children is limited, this research can aid in the 
knowledge of health bone development as well as potentially play a role in preventing 
disease states later in life.  
2.2.5.2 Adulthood 
Sclerostin has been shown to be higher in adult men than adult women regardless 
of age (18). Serum sclerostin levels are significantly lower in pre-menopausal women 
aged 30-34 than 35-39, and appears to be stable across the ages of 35-45 (80). In pre-
menopausal women, those who accumulated greater than 120 minutes of physical activity 
in a week showed significantly lower serum sclerostin levels than their inactive 
counterparts (81). Serum sclerostin levels display no association with BMD in pre-
menopausal women (82). Furthermore, there are no racial differences in sclerostin levels 
in pre- or post-menopausal women (42).  
The majority of research into the effects of sclerostin on human bone has involved 
older adults, particularly older women. Serum sclerostin levels are significantly higher in 
post-menopausal women than their pre-menopausal counterparts (36–42), though this has 
largely been shown in women not receiving estrogen therapies including oral 
contraceptives (37). In post-menopausal women, sclerostin was found to be negatively 
correlated to whole body BMD and BMC even when adjusted for age and BMI (81). In 
addition, sclerostin has been found to be elevated in female osteoporotic populations 
when compared to female non-osteoporotic populations (70), therefore, serum sclerostin 
has also been suggested as a predictor for fracture risk in post-menopausal women 
(33,81,83).  
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The literature concerning DKK-1 in human adults is scarce. DKK-1 is 
significantly higher in osteoporotic males and females compared to osteopenic males and 
females (54), and is also significantly higher in post-menopausal women who are 
osteoporotic compared to those who are not (84). DKK-1 is also  inversely correlated to 
bone mineral density in older female populations (54). However, limited research exists 
in this area and therefore, the mechanism by which DKK-1 is involved in aging is not 
well understood.  
In older adult populations, OPG is significantly higher in older women than older 
men, while no differences were seen in serum levels of RANKL (85). When comparing 
osteoporotic post-menopausal women to their non-osteoporotic counterparts, RANKL is 
significantly higher (86), however there appears to be no difference between these two 
groups in OPG concentrations (84). There also appears to be an increase in RANKL 
levels post-menopause when compared to pre-menopausal women and this relationship 
has been suggested to be due to the estrogen deficiency seen after menopause (70,74). 
Estrogen deficiency in menopause has also been suggested as the mechanism by which 
OPG levels are seen to decrease after menopause (74). Together, this net increase in 
RANKL:OPG could contribute to age-related bone loss.  
There is also limited evidence regarding the levels of and changes in TGF-β 
during adulthood. The research that is available appears to focus on TGF-β1 and its role 
in bone loss later in life. It has been shown that TGF-β1 is significantly higher in early 
menopause than late and pre-menopause (with no differences between late and pre) (87), 
and that in late menopausal women, there are no differences in TGF-β1 levels between 
individuals who are osteoporotic and those who are not (88). TGF-β1 is also not 
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associated with hip or total body BMD in older women and a significant linear positive 
relationship exists between TGF-β1 levels and fracture risk in older women, while a non-
linear negative relationship appears to exist between TGF-β1 levels and fracture risk in 
older men (89), posing a potentially interesting sex difference in TGF-β1 levels in older 
adults. 
2.3 Exercise and Bone 
It has been suggested that there are several factors that affect the clinical efficacy 
of exercise on bone remodelling, these being age, sex, diet and drugs, exercise intensity 
and type as well as time course of measurement and the presence of metabolic disorders 
(90). The following sections aim to address these factors and their effects on bone 
metabolism. 
2.3.1 Exercise and Bone Mineral Density 
Bone matrix micro-damage, which can be accrued through physical activity, 
stimulates remodelling and increases in bone strength. Physical activity is known to 
improve bone micro-architecture as well as influence bone geometry (1).  
Differences in bone accrual between participants of different sport types or 
between athletes and non-athletes in pediatric populations mainly appear after puberty 
(4,5,91,92). Additionally, there is a lack of consensus as to whether peak strain is a better 
indicator of increasing BMD than total physical activity (6).The Iowa Bone Development 
Study, a longitudinal bone health study that is currently ongoing, has suggested that a 
significant predictor of hip BMC is the amount of vigorous physical activity performed 
before the age of five in girls aged 13 and 15 (93).  
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In adolescent populations, there is less of a consensus than there is in adults on the 
effects of exercise on bone turnover. A recent review suggests that cumulative daily 
physical activity is not enough to explain differences in bone mass in female adolescents 
(6). Femoral neck BMD is only affected if physical activity in adolescence is carried over 
into adulthood and increases in lumbar spine bone mass is only associated with physical 
activity done in adulthood. In children, this relationship has again been shown to be 
largely sport or activity specific although the literature on exercise and bone turnover in 
younger children is very limited.  
In pediatric populations, cross sectional studies can give us a glimpse of the 
effects of exercise on BMD. Gymnastics is a high impact sport and those who participate 
in these sports have increased femoral neck BMD compared to other athletes exposed to 
extreme dynamic loading and/or weight bearing activity such as endurance running (94). 
This provides evidence that perhaps the repetitive dynamic loading of gymnastics is 
beneficial in the development of bone strength. However, there are differences in BMD 
across gymnastic specialties. Artistic gymnasts have higher BMD compared with 
rhythmic gymnasts, swimmers and age-matched non-athletic controls (76). Rhythmic 
gymnasts only demonstrate differences from controls and swimmers at the femoral neck 
(4), suggesting the higher dynamic loads of artistic gymnastics are required to see 
differences in total body BMD. Soccer and tennis, which dynamically load the lower and 
upper limbs respectively, demonstrate increased BMD compared to swimming and non-
athletic controls (91).  Synchronized swimming, a low-impact sport due to its aquatic 
nature, is shown to have no significant differences on bone speed of sound (an indicator 
of bone strength and therefore BMD) compared to age-matched controls (95).  
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Exercise intervention studies provide a better design to examine the effects of 
exercise on BMD. According to the systematic review conducted by Ludwa and Klentrou, 
(96), which included 35 exercise intervention studies, short-duration, high-impact 
exercise interventions undertaken early in childhood (pre and early puberty) have 
demonstrated a persistent long-term effect on BMD and BMC over and beyond that of 
normal growth and development. A recent meta-analysis by Ishikawa et al. (2013) 
examined the impact of weight-bearing exercise on areal bone mineral density (aBMD) 
and BMC in young girls with the objective to quantify the influence of key moderating 
variables (e.g. pubertal stage, exercise mode, intervention strategy, exercise duration, 
frequency of exercise, program length and study design) on skeletal development. The 
authors analyzed 17 exercise training studies and concluded that interventions performed 
for more than 3 days per week and lasted for at least one year were more effective in 
promoting bone development in growing females (97). The meta-analysis by Behringer et 
al. (2014), which included 27 intervention studies, showed a significant effect of weight‐
bearing activities on BMC only in pre-pubertal children suggesting that the efficacy of 
training in terms of bone mineral accrual is substantially affected by the maturational 
status of participants(98).  Finally, the most recent systematic review published by 
Specker et al. (2015) included 22 exercise interventions and in consistence with the 
previous reviews, they also showed benefits on aBMD in pre-pubertal children but not in 
children who were early or post-pubertal (99).  
2.3.2 Exercise and Bone Turnover Markers 
The successful promotion of bone development via exercise is largely movement-
specific. Evidence in adults suggests that bone formation markers are extremely sensitive 
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to even minor changes in physical activity, such as the transition from performing no 
daily physical activity to adding walking to one’s daily routine (100). The majority of 
research on the relationship between exercise and bone turnover markers has not focused 
on the markers that will be investigated in this study, therefore the discussion that follows 
will concern more traditional bone turnover markers in the literature such as osteocalcin 
(OC) bone alkaline phosphatase (BAP), cross-linked C telopeptide and cross-linked N-
telopeptide (CTx and NTx respectively), tartrate-resistant acid phosphatase 5b (TRAP5b) 
and N-terminal type I pro-collagen (P1NP).  
2.3.2a Short Term Training 
The effects of short term training offers activity-specific insights into its 
relationship with markers of bone turnover (101). Small changes in bone turnover 
markers can be seen in just two weeks with decreases in TRAP5b as well as decreases in 
BAP while OC remains unchanged (102). A review found that five to eight weeks of 
endurance running appears to favour bone formation by decreasing bone resorption 
markers (101). Different training modalities appear to favour different changes in bone 
turnover markers, with 8 weeks of endurance training having minimal changes in markers 
of either formation or resorption while resistance training significantly increased BAP 
and OC following eight weeks of training. A combined aerobic and resistance training 
protocol increased BAP following eight weeks of training with increases in OC only 
being demonstrated at the midpoint of training (103). Ten weeks of military training (a 
combination of both aerobic and anaerobic exercise) in adult females saw increases in the 
formation markers BAP and PINP as well as increases the resorption markers CTx and 
TRAP (104). This indicates that the combination of anaerobic and aerobic exercise modes 
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led to a net increase in bone turnover. The type of resistance training appears to have an 
effect as well, as ten weeks of upper body resistance training alone showed no change in 
either markers of formation or resorption (105). Anaerobic and resistance training appears 
to have the overall effect of increasing bone formation by either favouring bone formation 
with no change or decreases in bone resorption (101). 
2.3.2b Acute Exercise 
The most responsive marker of bone turnover to acute exercise appears to be OC 
though the effects typically are determined by the type and duration of the exercise (106). 
In an acute session of plyometric training in untrained males, OC has been shown to be 
elevated five minutes and one hour following the cessation of exercise with similar 
elevations demonstrated in an eccentric protocol two hours, one day, three days and even 
five days after a high volume eccentric workload (107). Treadmill running has been 
shown to increase OC levels during exercise though concentrations of OC returned to 
baseline levels at the end of the exercise. OC then increased and recovered during a 
recovery period, with no changes at follow-up days (108) indicating differences in the 
response of OC to different types of exercise. Jogging has demonstrated no effect on OC 
levels in young women, though a response was seen in post-menopausal women (106). 
The effects of an acute session of exercise on BAP appears to be activity specific. 
Aerobic weight bearing sessions of jogging or treadmill running appear to be the mode to 
demonstrate changes in serum BAP with walking decreasing serum BAP 24 hours post-
exercise in young women (109). BAP has also been seen to increase immediately after 
jogging in post-menopausal women then returning to baseline after 24 hours, again 
confirming the specificity of activity needed to demonstrate elevations of BAP (106). The 
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addition of resistance exercise to a walking protocol increases serum BAP 24-hours post-
exercise (109). Resistance training appears to independently increase BAP only 
immediately after exercise, with markers of bone resorption significantly lowered one and 
eight hours following an exercise session, and no change in P1NP (110). Eccentric 
exercise (whether high or low volume) appears to have no effect on serum BAP both 
immediately or on follow-up days (107). 
P1NP is one of the few measures studied acutely in children. In boys, it is 
unchanged after a single exercise bout (9). An acute session of weight bearing exercise 
(treadmill running) has been shown to increase P1NP significantly in adult males during 
exercise wherein it decreases rapidly and significantly during the recovery period of four 
days (108).  
2.3.3 Exercise and Factors Related to the Wnt Pathway 
The main function of the osteocyte is largely mechanosensory (21), and 
mechanical loading is one of the most convincing regulators of sclerostin expression by 
Sost (18). Mechanical loading in the animal model has been shown to decrease sclerostin 
expression by the Sost gene resulting in increased bone formation (2,21,22,24–
26,32,111).The local distribution of osteocytes producing sclerostin can control the 
formation of new bone whether or not bone remodelling will take place, indicating that 
the relationship between sclerostin and bone remodelling has a site-specific mechanism 
(21,25,26,111). Several animal trials have indicated that joints experiencing high peak 
strain when mechanically loaded show higher reductions in sclerostin levels within the 
osteocytes compared to joints exposed to lower peak strains when mechanically loaded 
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(2,111). A linear relationship between amount of local mechanical loading and the 
subsequent local sclerostin response has also been postulated (2). 
The research regarding the relationship between exercise and DKK-1 is scarce. It 
has been reported that in adults, resistive exercise may have an effect on DKK-1, but the 
study was too small to detect any significant changes (112) and therefore the effects of 
exercise on DKK-1 are relatively unknown. 
The literature regarding the relationship between TGF-β and exercise is scarce. 
However, one study has shown that TGF-β appears to be responsive to strenuous physical 
activity. Evidence in young adult males performing strenuous cycling ( a mode of 
exercise that is of a high intensity but low mechanical load) indicates that TGF-β 
increases significantly immediately after a bout of strenuous exercise and remains 
elevated two hours after the cessation of the exercise bout (113).  
Exercise (or the lack of) is capable of increasing levels of RANKL within the 
osteocyte (32). In post-menopausal women performing 8 months of either resistance or 
aerobic weight bearing exercise, no changes are seen in levels of OPG, RANKL or in the 
ratio between the two markers (114). Another study showed that 32 weeks of combination 
of resistance and balance training in older adults significantly increased levels of OPG in 
women but not men, with no changes in RANKL in either group (85). Exercise that is of 
low impact but also of high intensity is capable of increasing OPG and RANKL 5 min 
after an exercise session, but both markers return to baseline within 24 hours in healthy, 
recreationally active males (3). A recent study determined that an acute session of 
plyometric exercise significantly increased BAP and OPG in both boys and men, but that 
 26 
 
the time course of this increase was different between the two age groups; whereas 
RANKL was not significantly different between boys and men, nor was it different after 
exercise. It was therefore postulated that an acute session of plyometric exercise was 
sufficient to stimulate bone formation in both boys and young men (115). 
2.4 Growth and Development 
2.4.1 Role of Biological Sex on Growth and Development 
Biological sex is an important uncontrollable factor when it comes to bone mass 
and bone turnover. Cortical BMD is significantly greater in adolescent and adult females 
when compared to males of the same age with medium to large effect sizes for the female 
sex on bone mass-related variables (116). A medium-large effect size for the male sex is 
present for rates of bone formation and resorption. Adolescent males have higher 
concentrations of bone turnover markers (both formation and resorption) thus leading to 
an increased rate of bone turnover (116). Markers of bone formation also peak at different 
ages between males and females. Serum bone biomarkers peak at Tanner stage II in girls 
and Tanner stage III in boys (117). BAP peaks around the age of 9 in girls and 12 in boys, 
while OC peaks at 12 in girls and 13 in boys, with significant decreases in the serum 
levels of these markers following peak levels (118). However, it has also been suggested 
that bone mass is only associated with bone turnover markers in Tanner stage I, 
suggesting biological sex is not the only factor affecting growth and bone turnover (117).  
The relationship between bone turnover and menstrual phase is important to 
consider in females. Estrogen increases the sensitivity of bone to mechanical loading 
(119) and also appears to be the main factor influencing BMD and BMC in both pre-
pubertal boys and girls (120).  Early in the follicular phase, bone turnover markers such 
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as CTx and OPG are suppressed. In the luteal phase and during ovulation, these 
resorption markers decrease, following an inverse relationship with estrogen fluctuations 
during difference phases (119,121). The differences in estrogen between pre-menarche 
and post-menarche girls can be accommodated by measuring post-menarche girls during 
the follicular phase when estrogen is low (122).  
2.4.2 Controllable Factors 
Pharmacological agents for conditions other than osteoporosis and other bone 
disorders can influence BMD and bone health. Anti-hyperglycemic medications use to 
treat diabetes can have differing effects. Metformin has been postulated to increase BMD 
and therefore decrease fracture risk whereas GLP-1 and DPP-4 are thought to have no 
impact on bone health (123). Treatments such as insulin, thiazolidinediones, and SGLT-2 
have been shown to increase fracture risk either by increasing hypotension (SGLT-2) or 
decreasing BMD (thiazolidinediones). (123). Finally, anti-epileptic medications have 
demonstrated convincing osteopenic effects, with both enzyme-inducing antiepileptic 
medications and non-enzyme-inducing antiepileptics showing decreases in BMD (124).  
Oral contraceptive use also plays a role in bone turnover as well as BMD. Use of 
oral contraceptives containing estrogen have shown significant decreases in markers of 
bone turnover (125,126), however spinal BMD appears to remain unchanged, even after 
six (127) or twelve (128) months of use. Exercise may provide a protective effect against 
this decrease in bone turnover (125) and oral contraceptive use may be protective against 
losses in bone strength associated with eating restraint (129). Long term use of oral 
contraceptives containing estrogen may also decrease BMD by allowing an inadequate 
amount of bone mineral accrual (125). Research concerning oral contraceptive containing 
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only progestin provide no clear evidence for their role in bone turnover, though it is 
speculated they may increase levels of bone resorption markers (125).  
Calcium and Vitamin D are the most common dietary components that can affect 
BMD. Unfortunately, a large population study found that only 17% of Canadian children 
aged 9-13 are meeting the adequate intake for calcium (130). Calcium is of particular 
importance in the stages of early puberty as bone mineral absorption and deposition rates 
peak just before menarche (131). Mild pediatric Vitamin D deficiency is detrimental to 
bone mineral accrual (131) and is also important as Vitamin D needs to be present in the 
body in order to see the full benefits of adequate dietary calcium (132), such as optimal 
growth and increased BMD. Increasing calcium consumption through diet and/or 
supplementation has been shown to potentially have greater longer term effects when 
taken earlier in puberty than later (131).  
Lastly, as previously mentioned, physical activity is a strong controllable factor in 
promoting bone turnover and formation, particularly in the formative years. It would 
appear that a window of opportunity exists in the pre-pubertal stages for girls, where 
greater increases in BMC at the femoral neck and lumbar spine have been seen with 
impact exercise compared to their mid-pubertal counterparts (8,133). Jumping exercise 
has been shown to increase hip BMD in both boys and girls (134) and longitudinal studies 
have indicated that long term physical activity contributes to greater increases in BMC in 
both boys and girls (135,136) with the greatest effects of physical activity being seen at 
weight bearing sites such as the tibia and femoral neck (136).  
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Chapter 3: Methods 
3.1 Participants 
This study and all related procedures received ethical clearance from the Brock 
University Biosciences Research Ethics Board (REB 14-267 KLENTROU). Twenty-six 
females (14 girls and 12 adolescents) completed the study. Participants were recruited 
through poster advertisements, newspaper ads and word of mouth. Recruitment of 
participants was focused on recreationally active girls and adolescents to limit the effects 
of elite or high volume sport participation on markers of bone turnover. Exclusion criteria 
included factors known to influence bone turnover properties: (1) BMI ≥ 90% percentile 
for their age, (2) previous (within last 6 months) or current fracture, and (3), 
pharmaceutical use of agents which may affect bone.  
3.2 Procedures 
All testing took place at the Applied Exercise Physiology Laboratory of Brock 
University. Participants were asked to refrain from consuming caffeine and alcohol for 6 
hours prior as well as refraining from vigorous or high impact exercise for a minimum of 
24 hours prior to testing. The first visit began between 8 and 9 am for all participants in 
order to control for circadian rhythm variation. Upon arrival, participant and 
parents/guardians were familiarized with the purpose of the study, the measurements 
involved, and any potential risks or benefits. The informed consent form was signed by 
the parent/guardian and the informed assent form signed by the participant.  
After obtaining consent and assent, the resting blood sample was drawn using a 
standard venipuncture technique. Anthropometric measures of height, seated height and 
weight (kg), as well as body composition were performed. A questionnaire package 
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including medical history, Godin-Shephard Leisure Time Exercise Questionnaire, Food 
Frequency Questionnaire and pubertal Stage questionnaire were completed by all 
participants, with parental/guardian help if needed. The plyometric exercise protocol was 
then completed and followed by two post-exercise blood samples, 5 min post-exercise 
and 60 min post exercise. During the second visit, the last blood sample (24 hours post-
exercise) was taken. 
3.3 Exercise Protocol 
The exercise protocol has been designed to provide high-impact, weight bearing 
loads in the form of circuit training stations. By following this protocol, a minimum of 
100 jumps were executed. This protocol was previously used in our lab by Kish and 
colleagues (10) that was adapted from MacKelvie and colleagues in their longitudinal 
school-based interventions (8) that has been successful in eliciting a bone response in 
pediatric populations.  
The participants began the session with a warm-up that included 5 min of low 
intensity cycling. Once the warm-up was completed, participants were given a 
comprehensive explanation and demonstration of each of the exercises. Following this 
explanation, the participants were allowed to familiarize themselves with the exercises to 
control for learning effects and to avoid injury.  
Each participant was instructed to rotate through each of the five stations 
(Jumping jacks, lunge jumps, hopping, tuck jumps and drop jumps) three times for a total 
of three sets. Jump height was tailored to each participant based on body size. The 
participant was at each station for approximately two minutes before she was instructed to 
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move to the next station. There was a rest period of three minutes between each set. 
Previous work has demonstrated that the ground reaction forces involved in such as 
circuit typically involves three to five times body weight (7) and is, therefore, a sufficient 
stimulus to induce a detectable bone response.  
3.4 Measurements 
3.4.1 Anthropometry and Body Composition  
Height and seated height were measured to the nearest 0.1 cm using a stadiometer, 
with no shoes and light clothes. Body mass (kg) as well as body composition including 
lean body mass (LBM), fat mass (FM) and percent body fat (%BF) were measured using 
the InBody520 bioelectrical impedance analysis (BIA) system (Biospace.228). Body 
mass index was calculated by dividing the participant mass in kilograms by their height 
squared in metres. Waist to hip ratio is calculated by dividing the circumference of 
narrowest point measured at the waist (in cm) by the widest point of the circumference of 
the hips (also in cm).  The same investigator performed all measures of height (cm), 
seated height (cm), weight (kg) and body composition for all participants. 
3.4.2 Indicators of Maturity 
Sexual maturity was self-assessed using secondary sexual characteristics (pubic 
hair and breast development) according to Tanner Staging (137). Somatic maturity was 
assessed by calculating years from age of peak height velocity (PHV), using height, 
seated height, leg length, as well as body mass (138).  
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3.4.3 Physical Activity Measures 
Leisure time physical activity was assessed using the Godin-Shephard Leisure 
Time Exercise Questionnaire. This questionnaire evaluates leisure time physical activity 
using indicators of the intensity of exertion as light, moderate or strenuous (139). From 
the answers provided by the participants, weekly physical activity metabolic equivalent 
(WAeq) can be assessed based on the number of 15 min blocks at each intensity level. The 
number of blocks at each intensity level is then converted to metabolic equivalents (139). 
The Godin-Shephard Leisure Time Exercise Questionnaire has been demonstrated to be 
valid and reliable in male and female pediatric, adolescent as well as adult populations 
(140).  
3.4.4 Dietary Intake Measures 
Dietary intake was evaluated using a food frequency questionnaire. Specifically, 
the Block Questionnaire for Children is designed to assess dietary habits through a recall 
of foods eaten in the last week and has shown to be a valid nutritional assessment in a 
pediatric population (141). Pictures are provided of portion sizes to enhance accuracy. 
The adolescent participants used the Adult Block Questionnaire 2014. All responses were 
analyzed by NutritionQuest (NutritionQuest, USA) providing estimates of total energy 
intake (kcal/day). 
3.4.5 Biochemical Markers 
Venous blood samples were collected from the antecubital fossa of each 
participant using a standard venipuncture technique between 8:00 am and 9:00 am to 
avoid circadian rhythm variations in bone turnover markers. The first sample (pre-
exercise) contained eighteen millilitres of blood and all remaining samples contained ten 
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millilitres of blood (post-exercise samples). Serum was collected using SST vacutainers. 
One pre-exercise, and three post-exercise blood samples were collected at 5 min, 60 min 
and 24 hours following the exercise bout. The blood was allowed to clot for 30 min at 
room temperature before being centrifuged for 15 min at 4˚C at 1000 x gravity. The 
serum was then separated and aliquoted into 1.5ml polyethylene tubes which were then 
stored at -80°C until analysis. To test for potential post exercise hemoconcetration, pre 
and post exercise hematocrit measurements were performed in 6 participants and no 
changes in plasma volume were observed.  
Serum samples were analyzed for biochemical markers. The following osteokines 
were measured using Milliplex MAP kits: sclerostin, DKK-1, OPG and RANKL. The 
following growth factors were also analyzed using Milliplex MAP kits: TGF-β1,2 and 3. 
The use of Milliplex kits allows for efficient use of time, as several markers can be 
measured on the same plate (Human Bone plate containing sclerostin, DKK-1 and OPG 
as well as a RANKL plate and a TGF-β plate containing TGF-β1,2 and 3). Since these 
kits are capable of detecting pediatric concentrations of these markers, serum was diluted 
according to kit-specific instructions.  
All samples and kits were brought to room temperature prior to the initiation of 
the analysis procedure. All analyses were performed in triplicate due to the nature of a 
Milliplex kit and concentrations were read using a MAGPIX ® xPONENT ® plate 
reader.  
Sclerostin, DKK-1 and OPG were assayed using 5 Milliplex ® MAP Human 
Bone Magnetic Bead Panel kits (EMD Millipore Corporation, Billerica, MA, USA). The 
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procedure of this assay is split over two days. On the first day, all reagents necessary were 
brought to room temperature and reconstituted. When completed, the plate was then 
sealed with a plate sealer, wrapped in foil and left to incubate for 16-18 hours on a plate 
shaker at 4˚C. The following morning, all remaining reagents were removed from the 
fridge and allowed to warm to room temperature. The plate was then read using 
xPONENT ® software for the MAGPIX ®. The intra-assay coefficients of variability for 
sclerostin were 1.86%, 11.96%, 23.34%, 0.65%, 1.14% and 23.75%, respectively. The 
inter-assay coefficient of variation for sclerostin was 9.0 %. The intra-assay coefficients 
of variation for DKK-1 were 0.16%, 1.75%, 13.24%, 5.03% and 0.18%, respectively. The 
inter-assay coefficient of variation for DKK-1 was 18.5%. The intra-assay coefficients of 
variation for OPG were 0.09%, 0.44%, 1.01%, 2.13% and 21.44%, respectively. The 
inter-assay coefficient of variation for OPG was 12.1%. 
Nuclear factor kappa B ligand (RANKL) was assayed using 5 Milliplex ® MAP 
Human Bone Magnetic Bead Panel kits (EMD Millipore Corporation, Billerica, MA, 
USA). The procedure of this assay is split over two days. On the first day, all reagents 
necessary were brought to room temperature and reconstituted. When completed, the 
plate was then sealed with a plate sealer, wrapped in foil and was left to incubate at 4˚C 
for 16-20 hours with agitation. The following morning, all remaining reagents were 
removed from the fridge and allowed to warm to room temperature. The plate was then 
read using xPONENT ® software for the MAGPIX ®. The intra-assay coefficients of 
variation were 0.89%, 4.6%, 2.9%, 1.11% and 12.3%, respectively. The inter-assay 
coefficient of variation was 12.8%. 
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Transforming Growth Factor β1, 2 and 3 was assayed using 5 Milliplex ® MAP 
TGFβ 1,2,3 Magnetic Bead kits (EMD Millipore Corporation, Billerica, MA, USA). The 
procedure of this assay is split over two days. On the first day, all reagents necessary were 
brought to room temperature and reconstituted. When completed, the plate was then 
sealed with a plate sealer, wrapped in foil and was left to incubate at 4˚C for 16-18 hours 
with agitation. The following morning, all remaining reagents were removed from the 
fridge and allowed to warm to room temperature. The plate was then read using 
xPONENT ® software for the MAGPIX ®. The intra-assay coefficients of variability of 
TGF-β1 were 0.41%, 0.99%, 1.25%, 6.9% and 5.14% respectively. The inter-assay 
coefficient of variation was 18.3%. The intra-assay coefficients of variation for TGF-β2 
were 1.08%, 0.62%, 0.62%, 5.82%, and 0.35%, respectively. The inter-assay coefficient 
of variation was 19.1%. The intra-assay coefficients of variation for TGF-β3 were 0.59%, 
1.23%, 0.09%, 4.09% and 4.35%, respectively. The inter-assay coefficient of variation 
was 19.9%. 
3.5 Statistical Analysis 
All variables were normally distributed and no outliers were present in the data. 
Independent t-tests were used to examine differences between groups in anthropometric 
measures, habitual physical activity, nutrition intake as well as baseline measures of bone 
markers. A two-way repeated measures analysis of variance (RM ANOVA) with group as 
the between-subject effect and time the within subject effect was used to assess group 
differences over time for sclerostin and other osteokines. Post hoc analysis was used if 
significant main effects were detected. For each group, mean values at each time point 
were used for analysis. Missing values (n = 12 of 56 for the girls, n = 6 of 48 for the 
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adolescents) were accounted for using the group’s mean value for that particular time 
point. Missing time points were created if a blood sample was unable to be taken at a 
particular time point. If the assumption of sphericity for a particular case is not met, the 
Greenhouse-Geisser test of significance was used. If the assumption of equality of 
covariance is not met, than Pillia’s Trace test of significance was used. Data are reported 
as means and standard errors. Significance was assumed at an alpha level of 0.05. The 
observed power of this study was 0.850.  Statistical analysis was performed using SPSS 
version 22.0 for Windows. 
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Chapter 4: Results 
Participants’ physical characteristics are presented in Table 1. As expected, the 
girls were significantly younger, shorter and had a lower percent body fat than the 
adolescents. There were also significant differences in measures of somatic maturity (age 
from peak height velocity) and sexual maturity (Tanner stage), with the adolescents 
significantly further along in their growth and development. There were no significant 
differences in waist to hip ratio (a measure of the distribution of adiposity). Tanner Stage 
was unavailable for one girl in the adolescent group. 
Table 1. Physical characteristics of girls and adolescents. 
 Girls (n=14) Adolescents (n=12)  P 
Age (years) 10.5 ± 1.8 15.0 ± 1.0 <0.0001* 
Height (cm) 145.7 ± 11.2 163.3 ± 7.7 <0.0001* 
Weight (kg) 37.5 ± 9.4 59.9 ± 8.4 <0.0001* 
Body Fat (%)  16.9 ± 6.0 25.4 ± 8.1 0.0100* 
Age from PHV 
(years) 
-1.1 ± 1.5 2.4 ± 0.7 <0.0001* 
Waist to Hip Ratio 
(cm) 
0.7 ± 0.0 0.8 ±0.0 0.8310 
Pubertal stage 
(n in stage 
1,2,3,4,5) 
8,2,4,0,0 0,0,3,3,5  
All values are presented as mean ± standard deviation 
*indicates a significant difference between groups 
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Table 2. Habitual physical activity, dietary calcium, dietary Vitamin D and total 
energy intake of girls and adolescents. 
 Girls (n= 14) Adolescents (n=12)  P 
METs per week 100.14 ± 36.5 92.4 ± 34.7 0.606 
Calcium (mg/d) 592.33  ±  199.7 1348.71 ± 706.7 0.001* 
Vitamin D (IU/day) 110.7 ± 61.9 254.3 ± 168.4 0.007* 
Total Energy 
Intake (kcal/d) 
1150.67 ± 284.1 2208.39 ± 1079.7 0.002* 
All values are presented as mean ± standard deviation 
*indicates a significant difference between groups 
There were no differences between groups in leisure time physical activity as assessed by 
the Godin Shephard Leisure Time Exercise Questionnaire (Table 2). All participants were 
recreationally active and none were competitive athletes in high impact sports such as 
gymnastics. In addition, there was no correlation between reported leisure time physical 
activity and baseline levels of osteokines or growth factors. Significant differences 
between groups are present in daily calcium intake, daily vitamin D intake as well as total 
daily energy intake; in all cases the girls had lower intakes than the adolescents group 
(Table 2).  
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Table 3. Resting serum levels of osteokines and transforming growth factors (TGF-
β) in girls and adolescents. 
All values are presented as mean ± standard deviation 
*indicates a significant difference between groups using t-test. 
At baseline, there were no group differences in sclerostin, OPG and RANKL 
(Table 3). Significant differences were detected in DKK-1, TGF-β1, TGF-β2 and TGF-β3 
with the girls displaying higher levels of these markers in all four instances than the 
adolescents (Table 3).  
 
Biochemical 
Marker 
Girls Adolescents p value 
Sclerostin (pmol/L) 31.52  ± 6.2 32.53 ± 3.4 0.618 
DKK-1 (pmol/L) 29.76 ± 6.5 23.36 ± 4.8 0.010* 
OPG (pmol/L) 10.70 ± 5.1 8.41 ± 3.3  0.196 
RANKL (pmol/L) 2.48 ± 0.4 2.47 ± 0.7 0.956 
TGF-β1 (ng/ml) 0.238 ± 0.06 0.164 ± 0.08  0.015* 
TGF-β2 (ng/ml) 0.022 ± 0.0 0.016 ± 0.0  0.002* 
TGF-β3 (ng/ml) 0.0005 ± 0.0  0.0004 ± 0.0  <0.0001* 
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Figure 5. Sclerostin response to the plyometric exercise in girls and adolescents. 
All values are presented as mean ± standard error.  
 
There was no significant interaction (p>0.05) and no significant group effect for 
sclerostin (p>0.05) (Figure 5). There was a trend towards a main time effect (p=0.075). 
The observed power for sclerostin was 0.761. 
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Figure 6. DKK-1 response to the plyometric exercise in girls and adolescents. 
All values are presented as mean ± standard error;  
* indicates a significant difference between groups  
# indicates a significant difference between time points 
 
There was no significant interaction (p>0.05) for DKK-1. A significant group 
effect (p=0.016) was present for DKK-1. Post hoc analysis revealed a significant 
difference between groups pre exercise (p=0.010), as also shown in the t-test analysis, as 
well as 24 hours post exercise (p=0.015) with girls displaying significantly higher levels 
of DKK-1 than adolescents. There was also a significant effect for time (p=0.011) with a 
significant decrease at 24 hours post-exercise compared to baseline levels of DKK-1 
(p=0.013) in both groups (Figure 6). The observed power for DKK-1 was 0.756. 
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Figure 7. OPG response to the plyometric exercise in girls and adolescents. 
All values are presented as mean ± standard error. 
 
There was no significant interaction (p>0.05) and no group effect (p>0.05) found 
for OPG. However, there was a trend towards a significant effect for time (p=0.069) 
(Figure 7). The observed power for OPG was 0.480. 
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Figure 8. RANKL response to the plyometric exercise in girls and adolescents. 
All values are presented as mean ± standard error. 
# indicates a significant difference between time points 
 
There was no significant interaction (p > 0.05) and no a significant group effect 
for RANKL (p>0.05). The effect for time was significant (p=0.001) with post hoc 
analysis revealing a significant overall decrease 5 min post exercise (p=0.014) that 
remains lower 1 hour (p=0.048) and 24 hours (p=0.012) following exercise compared to 
pre-exercise values in both groups (Figure 8).  The observed power for RANKL was 
0.997.  
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Figure 9. TGF- β1 (a), TGF- β2 (b) and  TGF- β3 (c) response to plyometric exercise 
in girls and adolescents. 
All values are presented as mean ± standard error 
*indicates a significant difference between groups 
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There was no interaction (p>0.05), group (p>0.05) or time effect (p > 0.05) for 
TGF- β1 (Figure 9a). There was no interaction (p > 0.05), or time effect (p > 0.05) for 
TGF-β2, however the group effect was significant (p=0.010) with post hoc analysis 
revealing significantly higher levels in the girls at baseline (p=0.002) (Figure 9b). There 
was no interaction effect (p>0.05), or time effect (p>0.05) for TGF-β3, but there was a 
significant main effect for group (p=0.003) with the post hoc analysis revealing the girls 
displaying higher levels at baseline (p<0.0001), 5 min (p<0.0001), 1 hour and 24 hours 
(p<0.0001) post exercise (Figure 9c). The observed power for TGF-β1, TGF-β2 and TGF-
β3 was 0.619, 0.176 and 0.549 respectively.  
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Chapter 5: Discussion 
This is the first study to examine the response of bone biomarkers (i.e., osteokines 
and transforming growth factors) associated with the anabolic Wnt signalling and the 
catabolic RANKL pathway in girls and adolescent females to a plyometric exercise 
session. The main findings of this study are as follows: (1) girls had higher resting levels 
of DKK-1, TGF-β1, TGF-β2 and TGF-β3; (2) DKK-1 significantly decreased 24 hours 
following exercise and RANKL decreased 5 min post exercise and remained suppressed 1 
hour and 24 hours following exercise while sclerostin, OPG and all three isotopes of 
TGF-β were unresponsive to exercise in both girls and adolescents; and (3) the direction 
and timing of the exercise induced changes are not significantly different between groups 
for OPG, RANKL and DKK-1.  
5.1 Physical Activity and Nutrition 
There were no significant differences between groups in METs per week as 
assessed by the Godin-Shephard Leisure Time Exercise Questionnaire. METs per week 
did not significantly correlate with baseline measures of biochemical markers in either 
group. Girls have significantly lower daily energy intakes as wells as lower daily intakes 
of calcium. The recommended dietary allowance for calcium for children aged 4-8 years 
is 1000 mg/day and for girls aged 9-18 years is 1300 mg/day (142). The girls fall well 
below the recommended dietary allowance while the adolescent group just reaches an 
adequate daily amount of calcium. The recommended dietary allowance for Vitamin D 
for females aged 1-18 years of age is 600 IUs per day (142). Though significant 
differences in Vitamin D intake are present, neither group comes close to the daily 
recommended intake. This is typical of an adult Canadian population, where it has been 
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shown that daily sun exposure and daily dietary intake are insufficient to meet Vitamin D 
requirements (143).  For total energy intake the results are much the same; The girls fall 
below the recommended intake for active females aged 8-11 years while the adolescents 
meet the recommended intake (144). Since the girls are reporting approximately half the 
recommended daily caloric intake as well as daily calcium intake, it is possible that this 
group as a whole is underreporting their diet when using a food frequency questionnaire. 
This could also account for the fact that the Vitamin D levels in the girls are 
approximately half those reported by the adolescents.  
5.2 Anabolic and Catabolic Osteokines and Transforming Growth Factors 
In regards to the inhibitors of the Wnt signalling pathway – i.e., sclerostin and 
DKK-1 – our hypothesis was confirmed for DKK-1 only. DKK-1 was significantly higher 
in the girls compared to the adolescents whereas no group differences were seen in resting 
levels of sclerostin.  
The sclerostin results reported here are considerably higher than those reported by 
Kirmani et al. (75), who investigated differences in sclerostin between males and females. 
However, the age range of the participants of their study was considerably wider (4-21 
years) than the age rage in our study (8-16 years). Our sclerostin levels are also higher 
than those reported in eumenorrheic and amenorrheic athletes aged 15-21 years (76), 
albeit our participants are considerably younger. Our results for both groups are similar to 
those previously reported in healthy controls compared to HIV positive boys and girls 
(145), with an average age closer to our own (11 years of age). In contrast, Falk et al. (9) 
reported considerably lower levels of sclerostin in pre-pubertal and mid-pubertal boys, 
which is in contrast to the finding in the literature that males have higher levels of 
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sclerostin than females (18). Since such limited research exists, particularly in pre-
pubertal populations, more research is needed to establish accepted baseline values for 
sclerostin for both males and females at different stages of development.  
Two studies have reported resting DKK-1 levels in children (average ages of 11 
and 13 years respectively), both of which examined DKK-1 in altered states; one study 
compared obese and non-obese children and the second study compared HIV positive and 
HIV negative children (145,146). Both studies reported combined results for boys and 
girls as well as for pre- and post-pubertal. Our baseline results for the girls are in line with 
DKK-1 results of the HIV-negative children reported by Mora et al. (145), though the 
adolescent group demonstrates higher levels than those reported. The opposite is true of 
the study done by Radetti and colleagues, where their normal weight controls had similar 
results to our adolescent group while the girls displayed values lower than those reported 
(146). Since very limited research exists on resting DKK-1 levels in children, acceptable 
ranges for baseline values are unavailable. 
In regards to the markers involved in the RANKL pathway, our hypothesis of 
group differences was not confirmed. There were no differences between groups in 
baseline measures of OPG and RANKL. This confirms the results of Wasilewska et al., 
who found no group differences between girls and boys as wells as older and younger 
children (147). Since there is limited research available in the pediatric population, 
acceptable baseline ranges are currently unknown. Our OPG levels are considerably 
higher than those previously reported in pre-pubertal boys (10) and adolescent females 
(77). Our RANKL levels are considerably lower than those reported in pre-pubertal boys 
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(10), and slightly higher than the adolescent females reported by Lucas and colleagues 
(77). 
Our hypothesis of group differences was confirmed for all three isotopes of TGF-
β. Specifically, TGF-β1, TGF-β2 and TGF-β3 were all significantly higher in the girls 
than the adolescents. We hypothesized that girls would display higher levels of TGF-β 
simply because they have not yet reached somatic maturity (as demonstrated in age from 
peak height velocity). Our study is the first to compare resting levels of transforming 
growth factors in a healthy pediatric population. More research is needed to confirm these 
results as the majority of research into TGF-β is in disease states.  
5.3 Exercise Response 
The unresponsiveness of sclerostin to plyometric exercise confirms the results of 
Falk and colleagues in pre-pubertal boys (11). Furthermore, we found an overall decrease 
in DKK-1 over 24 hours following the plyometric exercise session. This is the first study 
to investigate levels of DKK-1 in response to exercise in a pediatric population and is also 
the first study to demonstrate the potential of plyometric exercise to suppress this Wnt 
inhibitor. Such suppression could potentially indicate the ability of plyometric exercise to 
suppress biochemical markers that inhibit Wnt signalling and therefore promote bone 
formation following exercise.  
No changes over time were seen in the anabolic OPG. However, there was an 
overall decrease in the catabolic RANKL 5 min after exercise, which remained 
suppressed 1 hour and 24 hours following exercise. Kish and colleagues, also reported no 
changes in OPG after a plyometric protocol in pre-pubertal and mid-pubertal boys but in 
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contrast to our results, they found no changes in RANKL in pre-pubertal boys after 
exercise (10). These conflicting results could indicate the potential for a sex difference in 
the RANKL response to plyometric exercise in pre-pubertal boys when compared to girls 
as well as adolescent females. As RANKL is an indicator of osteoclast activity, this 
research potentially demonstrates the ability of plyometric exercise to suppress osteoclast 
activity in young females.  
No changes were seen over time following exercise in all three isotopes of TGF-β. 
It has been reported that TGF-β1 responded 2 hours after a bout of strenuous cycling in 
young adult men (113). It is possible that the acute exercise intensity required for a TGF-
β response in children may be greater than what was achieved in this protocol. Further 
research is needed to determine if indeed TGF-β is capable of responding to exercise in 
pediatric populations.   
A single bout of plyometric exercise is, therefore, a sufficient stimulus to affect 
factors associated with the Wnt pathway. The decrease in DKK-1 indicates that 
plyometric exercise is capable of withholding inhibitors of the Wnt pathway, allowing 
gene transcription in favour of bone formation to occur uninhibited. On the other hand, 
the interesting finding that sclerostin in unresponsive to plyometric exercise in children, 
which was also seen in boys by Falk and colleagues (11), suggests that inhibitors of the 
Wnt signalling pathway are not universally suppressed by the same type of exercise. The 
suppression of bone resorption indicators is also demonstrated in downstream factors 
such as RANKL (a known indicator of bone resorption), which was decreased almost 
immediately after exercise and remaining suppressed for a longer period of time. This 
decrease in RANKL led to an increase in OPG/RANKL ratio, suggesting a shift in favour 
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of bone formation without a parallel, significant increase in OPG. This immediate 
reduction in osteoclastogenesis independent of Wnt after plyometric exercise indicates 
greater bone turnover being initiated by an increase in bone resorption, which may be a 
pre-requisite to stimulate the Wnt signalling pathway, and a subsequent shift towards 
bone formation, through the suppression of catabolic osteokines such as DDK-1.  
 52 
 
Chapter 6: Conclusion 
6.1 General Conclusions 
This study found that in both girls and adolescent females, a single bout of 
plyometric exercise was sufficient to initially suppress (i.e., 5 min post-exercise) 
RANKL, a marker of osteoclastogenesis, which remained lower than baseline 24 hours 
following the exercise, when DKK-1, an inhibitor of the anabolic Wnt signalling, also 
dropped regardless of pubertal status. These results suggest that a single bout of 
plyometric exercise could be a sufficient stimulus to shift the bone anabolic/catabolic 
balance in girls and adolescent females. We also demonstrated group differences in DKK-
1 and TGF-β1, 2 and 3 with consistently higher levels in girls than adolescents, 
confirming our hypothesis of younger girls having an overall of a higher bone turnover 
rate.  
6.2 Strengths and Limitations 
There are several strengths of this study. First, the participants came into the study 
fasted and received a standardized breakfast after the baseline blood sample. This could 
potentially eliminate the immediate effects of nutrition on bone markers. Though this is 
not the first study to investigate the response of children to plyometric exercise, the 
previous studies only investigated the differences between pre-pubertal boys and men 
(10,11). By using a female population, we can add to the current literature regarding the 
relationship of plyometric exercise to bone in two distinct pediatric female populations. 
Another strength that was not included in the Kish et al. study was the comparison of girls 
before and immediately after sexual maturity. Since peak bone mass is accrued in early 
adulthood, the inclusion of a post-pubertal group who has presumably attained adult 
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height but not peak bone mass give a glimpse of the potential of plyometric exercise to 
positively influence bone metabolism before peak bone mass is achieved. The beginning 
of puberty is associated with periods of large bone growth (117) and the differences in 
response to plyometric exercise based on sexual maturation, to our knowledge, has not 
been shown in previous research. We also used a protocol that has been proven to elicit a 
bone response (8,10,11) and can be confident that the response in osteokines and growth 
factors we have seen is due to this protocol and not other lifestyle factors. We also 
controlled for circadian rhythm variations in bone bio markers by ensuring that our 
participants gave their first blood draw between 8 and 9 am.  
A limitation of this study is the coefficients of variation for inter- and intra-plate 
reliability. Though acceptable ranges for %CV for Milliplex kits are higher than 
traditional ELISA kits (approximately 10% for intra-plate reliability and approximately 
15% for inter-plate reliability) some of our coefficients are still slightly outside this range.  
6.3 Implications and Future Directions 
This study has demonstrated that plyometric exercise is capable of suppressing the 
catabolic osteokines DKK-1 and RANKL in pediatric females regardless of pubertal 
status. These results could aid the specification of physical activity guidelines for 
pediatric females in order to attain optimal bone mineral accrual throughout changes in 
puberty.  
We specifically aimed to address some of the gaps in the literature regarding 
resting values and the subsequent response to exercise of biochemical markers involved 
in both the anabolic Wnt and the catabolic RANKL pathways. This study has highlighted 
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the need for future research to confirm resting levels of serum osteokines such as 
sclerostin, DKK-1, OPG and RANKL in both male and female pediatric populations as 
well as investigate their responses to plyometric and other modes of exercise. This study 
was also the first to investigate resting levels of transforming growth factors in a healthy 
pediatric population. Further research is also needed to confirm these results as well as 
further investigate their role in Wnt signalling.  
Although this is the first study to demonstrate the response of Wnt signalling 
osteokines in pediatric females, there is very little known on the response of sclerostin to 
an acute session of exercise in adult females. Particularly of interest is the association of 
sclerostin with estrogen in post-menopausal women (148). Another area of interest would 
be the comparison of female athletes vs non-athletes, particularly where energy deficit 
may play a role.  
Another area of future research would be to investigate different modes of 
exercise on these osteokines and growth factors in both male and female pediatric 
populations. Cycling, for instance, does not create ground reaction forces of the same 
magnitude as plyometric exercise; however very high exercise intensities can be achieved 
through cycling which may have differing effects on the response of the growth factors 
and bone biomarkers examined here.  
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Appendix 1: Recruitment Materials 
1.1 Poster 
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1.2 Newspaper Ad 
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1.3 Invitation Letter 
 
Invitation Letter 
 
Effects of plyometric exercise on markers of bone turnover and inflammatory 
cytokines in girls and women 
Principal Investigator: Dr. Nota Klentrou, Faculty of Applied Health Sciences, Brock 
University 
Co-investigators: Dr. Bareket Falk, Dr. Andrea Josse-Obar, Jennifer Dekker, Rozalia 
Kouvelioti, Katlynne Nelson, Kathryn Denize 
 
If you have a female child between the ages of 8 and 16, we would like to invite you and 
your child(ren) to participate in this study.  
The purpose of this research project is to investigate the immediate response and 
subsequent recovery of bone metabolism and inflammation induced by a variety of 
jumping exercises over a period of 24 hours in women and girls.  
Tests and measurements will require 90 minutes on one day and 15 minutes on the post-
exercise day. In short, measurements will include filling out several questionnaires, 
completing a 30 min exercise routine and measurements of bone turnover using blood 
samples. 
Participation in this project will provide information such as height, weight, hip 
circumference, waist circumference and percent body fat. Participants will receive a $20 
compensation for their time and travel expenses. Parking is also provided. 
This research is being performed by researchers in the Applied Physiology Laboratory of 
Brock University. 
If you are interested in participating or if you would like more information, please fill out 
the form on the next page and return it in the enclosed envelope. You can also email the 
requested information to Jennifer Dekker (Project Coordinator) at jd10hc@brocku.ca or 
to Nota Klentrou (Principal Investigator) at nklentrou@brocku.ca 
This study has been reviewed and received ethics clearance through the Brock University 
Research Ethics Board (REB #14-267). If you have any pertinent questions about your 
rights as a research participant, please contact the Brock University Research Ethics 
Officer (905 688 5550 ext 3035 or reb@brocku.ca). 
 
Thank you, 
Dr. Nota Klentrou  
Department Kinesiology 
Faculty of Applied Health Science 
Brock University 
Tel: 905-688-5550 ext: 4538  
Email: nklentrou@brocku.ca  
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If you are willing to be contacted to discuss having your child participate in this study, 
please complete one of the two following options: 
 
OPTION 1: Fill out the information below and return this form in the enclosed envelope 
 
OPTION 2: Send the information below to Jennifer Dekker (Project Coordinator) at 
jd10hc@brocku.ca 
 
Child’s first and last name: 
 ______________________________________________________________ 
 
Child’s age:               ________________________________________ 
Child’s sex:               ________________________________________ 
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Appendix 2: Consent Forms 
2.1 Parental Consent Form 
 
INFORMATION AND CONSENT TO PARTICIPATE IN RESEARCH 
Effects of plyometric exercise on markers of bone turnover and 
inflammatory cytokines in girls and women 
You and/or your child are being invited to participate in a research study being conducted 
by the investigators listed below. Prior to participating in this study please read this form 
to find out the purpose and tests of this study. For the tests, you will have to visit the 
Applied Physiology Laboratory at Brock University. This study is a part of the Faculty of 
Applied Health Sciences (FAHS) of Brock University.  
PRINCIPAL INVESTIGATOR: DEPARTMENT   CONTACT 
Dr. Nota Klentrou  FAHS, Brock University  905-688-5550 ex. 
4538 
CO-INVESTIGATORS:  DEPARTMENT   CONTACT 
Dr. Bareket Falk   FAHS, Brock University  905-688-5550 
ex. 4979 
Dr. Andrea Josse-Obar  FAHS, Brock University  905-688-5550 
ex. 3502 
STUDENT CO-INVESTIGATORS: DEPARTMENT  
 CONTACT 
Jennifer Dekker   FAHS, Brock University  905 688-5550 
ex. 5623 
Rozalia Kouvelioti  FAHS, Brock University  905 688-5550 ex. 
5623 
Katlynne Nelson  FAHS, Brock University  905 688-5550 ex. 
5623 
Kathryn Denize   FAHS, Brock University  905 688-5550 
ex. 5623 
PURPOSE 
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The purpose of this study is to investigate the immediate response and subsequent 
recovery of bone metabolism and inflammation induced by jumping exercise over a 
period of 24 hours in children and adults. 
DESCRIPTION OF TESTING PROCEDURES 
If you agree to participate in this study, you will visit our laboratory, where you and/or 
your child will complete one 90 minute session of testing and another session 24 hours 
later, lasting 15 minutes. At the end of the study you will be given a summary of the 
findings upon request. Shorts, a short sleeved shirt and running shoes are recommended 
for the measurements. Parents may be present at all stages of the study.  
Participants will undergo the measurements and procedures listed below; please note that 
you may choose not to answer a question in any questionnaire.  
Pre-exercise Assessments 
 
1.) Participants will be asked to complete several questionnaires, outlining your 
general health, physical activity, nutritional habits, pubertal status and several 
psychological variables. The general health questionnaire screens if participants 
can safely participate in all of the required measurements, and offers us a better 
understanding of each participant’s general health that helps us properly interpret 
the data.  Please note that this questionnaire includes questions about smoking, 
alcohol consumption and drug use. In all questionnaires, participants may choose 
not to answer any question. The questionnaire used to measure pubertal status 
involves the participants looking at drawings of genetalia and deciding which 
stage of puberty they best match. This will be carried out in private to avoid any 
unease. The questionnaire regarding psychological variables includes questions 
asking about exercise and healthy eating motivations, physical self-perception and 
self-confidence regarding exercise and nutrition. 
2.) Body Composition: we will measure height, weight, hip circumference, waist 
circumference and percent body fat. Percent body fat will be estimated using 
bioelectrical impedance analysis (BIA) and the BodyMetrix system. The BIA 
assessment requires the participant to stand on a weight scale and grasp handles. A 
mild electrical current (50kHz, 800µA) will pass through hands to feet. This 
current cannot be felt and causes no harm. Valid measurements require abstinence 
from consuming caffeine and alcohol for 6 hours prior as well as refrain from 
vigorous or high impact exercise for a minimum of 24 hours prior to exercise 
testing. The BodyMetrix system uses ultrasound to accurately measure fat 
thickness at the thigh, waist and tricep. These measures are then used to 
calculate Body Fat % and weight distribution. There is no discomfort associated 
with this measurement. 
3.) A total of four (4) blood samples will be collected to assess biochemical markers 
of bone turnover and inflammatory cytokines: pre-exercise, 5 min post exercise, 
60 min and 24 hours post exercise. The blood samples will be drawn by a nurse or 
trained member of the research team using a standard technique. Up to 20 ml of 
blood will be withdrawn. It should be noted that the venous blood drawing 
procedure is a routine procedure performed by a nurse and offers minimal risk to 
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participants.  In rare instances, participants may experience slight pain and/or 
tingling in the area and/or a minor bruise from the needle. However, with the use 
of anaesthetic creams (e.g., Emla), which we use in the laboratory, any sensation 
of pain is minimal. Once samples are collected, we split them into air-tight smaller 
tubes and stored in a freezer until analysis. The freezer is located in a locked 
laboratory, which is only accessible to qualified personnel. We will hold onto 
these tubes for 5 years at which time they will be disposed by qualified, trained 
personnel and according to biosafety and University protocols. 
 
Exercise Protocol 
A heart rate monitor and accelerometer will be worn by the participant for the 
entire duration of the exercise session in order to assess intensity of the performed 
activity. The exercise session begins with a warm-up that includes 5 min of low 
intensity jogging and a series of dynamic stretches. The exercise protocol has been 
designed to provide high-impact, weight bearing loads in the form of circuit 
training stations. Each participant will be instructed to rotate through each of the 
five stations (Jumping jacks, lunge jumps, hopping, jumping over obstacles such 
as a bench and drop jumps) three times for a total of three sets. Jump height will 
be tailored to each participant based on body size. The participant will be at each 
station for approximately 2 minutes and the participant will then be instructed to 
move to the next station. A recovery period of 2 minutes will be given between 
each set. All exercise testing will be done in the presence of 2 study personnel, a 
tester and a spotter. 
 
CONFIDENTIALITY 
All data collected though this study will remain confidential and will be stored in 
locked offices and secured computers to which only the principal and co-investigators 
has access. You should be aware that the results of this study will be made available 
to other scientists though publication in a scientific journal, but your name and 
personal data will not appear in the compilation or publication of these results. A 
master list will be kept to link participants’ names with codes. This list and all data 
will be kept for 5 years after the date of publication, at which time all information will 
be confidentially destroyed. Additionally, you will have access to your own data, as 
well as group data when it becomes available and if you are interested. This can easily 
be provided to you by contacting the principal investigators.  
 
 
SECONDARY USE OF DATA 
Some of this data may be of use in the future for comparative purposes by colleagues, 
students or other researchers. The data used by these future researchers will remain 
anonymized, as all personal identifiers will have been removed. You may refuse to 
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allow your information to be used in the future and still remain a subject in this study. 
In this case, your data will be confidentially destroyed 5 years after the date of 
publication. 
Do you want your or your child’s data to be used anonymized (i.e., de-identified) 
in a future study?  
Please check one box: □ Yes, I want my data to be kept anonymized for future 
studies.  
 □ No, I do not want my data to be kept for future studies. 
 
PARTICIPATION AND WITHDRAWL 
Participants can choose whether or not to participate in this study and may remove 
their data from the study if they wish. They may do so at any time by contacting the 
principal investigator in writing (email or mail). Participants will receive pro-rated 
compensation in the event they withdraw. Participants may also refuse to answer any 
questions posed to them during the study and will still remain a subject in the study.  
 
RISKS AND BENEFITS 
Participation in this study will allow participants to become exposed to a research 
protocol, contribute to the advancement of science and gain personal and general 
knowledge about their own body. All the results will be provided to you upon request.   
The only foreseeable risks involved in participation include: 
a) Possible muscle soreness, muscle fatigue and/or joint pain within 48 hours of the 
exercise tests. This is likely to occur if your child is not a usual exerciser. If this 
does occur, it is only temporary and will dissipate within 2-3 days. Plyometric 
exercise involves high impact forces so a low risk for minor injury from the 
jumping exercise also exists. To minimize the risk, a spotter will be present at all 
time. Also, for any reason, the participant can request to not do a particular 
exercise if she does not want to. Our goal is to complete all the exercises, but it is 
also to maintain a positive and encouraging environment during testing. We will 
always ask how your child is doing following each exercise. 
b) In rare instances, participants may experience slight pain and/or tingling in the 
area and/or a minor bruise from the venous blood draw. Children and youth are 
also at a risk of fainting at the sight of or introduction of a needle. However, for 
the younger participants a butterfly needle will be used that does not look like a 
typical needle. Both the nurse and researcher will show the younger participants 
the butterfly needle and explain the procedure. Participants who are not allergic to 
medications may choose to use an aesthetic cream that usually has no side effects. 
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However, there is a small risk for minor effects such as burning, swelling, itching, 
or skin rash at application site. 
 
RIGHTS OF RESEARCH PARTICIPANTS 
You will receive a signed copy of this consent form. You may withdraw your consent to 
participate in this study at any time, and you may also discontinue participation at any 
time without penalty. In signing this consent form or in participating in this study you are 
not waiving any legal claims or remedies. This study has been reviewed and received 
clearance from the Brock University Research Ethics Board (file # REB 14-267). If you 
have any pertinent questions about your rights as a research participant, please contact the 
Brock University Research Ethics Officer (905 688-5550 ext 3035, reb@brocku.ca).  
 
INFORMATION 
 
Please contact Dr. Nota Klentrou at 906 688 5550 ext 4538, nklentrou@brocku.ca or 
Jennifer Dekker at 905 688 5550 ext 5623, jd10hc@brocku.ca if you have any questions 
about this study.  
 
 
 
I HAVE READ AND UNDERSTAND THE ABOVE EXPLANATION OF THE 
PURPOSE AND PROCEDURES OF THE PROJECT.  I HAVE ALSO RECEIVED 
A SIGNED COPY OF THE INFORMATION AND CONSENT FORM. MY 
QUESTIONS HAVE BEEN ANSWERED TO MY SATISFACTION AND I 
AGREE TO PARTICIPATE IN THIS STUDY. 
 
 
SIGNATURE OF PARENT/GUARDIAN     DATE 
 
 
PRINTED NAME OF PARTICIPANT 
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WITNESS        DATE 
In my judgment the participant is voluntarily and knowingly giving informed consent and 
possesses the legal capacity to give informed consent and participate in this research 
study. 
 
 
SIGNATURE OF INVESTIGATOR     DATE 
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2.2 Child Assent Form 
  
Child Assent to Participate in an Exercise and Bone Research Study 
Principal Investigator: Dr. Nota Klentrou, Faculty of Applied Health Sciences 
Co-investigators: Dr. Bareket Falk, Dr. Andrea Josse-Obar, Jennifer Dekker, Rozalia 
Kouvelioti,  
Katlynne Nelson, Kathryn Denize 
 
This form may contain words you do not understand. Please ask the study staff to 
explain anything you do not understand. 
 
What is this study about? 
We are doing a research study, which is a special way to find out how your body works. 
Your mom, dad or guardian knows I am going to ask you to join this study. We are trying 
to find out if a series of jumping exercises will result in stronger bones.  
On the first day we will ask you to come to Brock University where you will perform 
jumping exercises and you will complete various measurements for 90 minutes. No one 
outside our group will know the results of these measurements or the answers from your 
questionnaires. The next day you will come to the University for 15 minutes to give a 
blood sample. 
Do I have to be in this study? 
You do not have to be in this study if you don’t want to. 
If you don’t want to participate you can stop at any time but please let the study team 
know. There will be no bad feelings if you do not want to do this.  
If you want to be in this study, you will be asked to sign this form. 
What will happen in the study? 
On the first day we will ask you to complete various measurements such as height, 
weight, hip circumference, waist circumference and percent body fat and filling out 
several questionnaires. We will then take you through a series of jumping exercises. The 
exercise begins with 5 minutes warm-up that including jogging and stretching. Then you 
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rotate through each of five stations doing different jumps (jumping jacks, drop jumps, 
jumping over a bench etc.). You will do this three times for a total of three sets. You can 
rest between sets. The exercises are safe and will be done with the help of a demonstrator 
and a spotter. A nurse or trained member of the research team will take one blood sample 
before the exercise, and two being taken after the exercise. On the second day, we will 
ask for one more blood sample so we are able to see if your bones have changed 
following the jumping exercises.  
The questionnaires will ask for information about your health and physical activity, what 
you usually eat and how mature you are and how you feel about exercise and nutrition. 
The questionnaire used to assess how mature you are involves looking at drawings of 
private parts of your body and deciding which stage of you best match. You will do this 
alone in a private room and you will place the page in an envelope. In all questionnaires 
you may choose not to answer any question and you can still be a participant in this study. 
No one outside our group will know the results from these measurements or the answers 
from your questionnaires.  
Are there good things and bad things about participating in the study?  
All of measurements are safe but you may experience some discomfort during the blood 
sample but not for long. If you want, we can put a cream on your arm so that you do not 
feel any pain. Your muscles may be sore after the jumping exercise. The exercises are 
safe but sometimes you can get small injuries from jumping. This is why a spotter will be 
there to assist you. You can also skip any exercise that may hurt you. 
 
Who will know that you are in the study? 
 
We will write papers about what we will find out and share the information with other 
researchers, but will not use your name when we talk about the results. 
 
Do you want to be in this study? Is this OK? 
Please check one box:   □ Yes, I want to be in the study. 
     □ No, I do not want to be in the study. 
I understand that I will receive a signed copy of this form. 
Name of child (please print):  
 
Signature of child: 
Date:  
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Investigators Signature: 
Date: 
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Appendix 3: Questionnaires 
3.1 Medical History Questionnaire 
SUBJECT SCREENING AND MEDICAL HISTORY QUESTIONNAIRE 
Name: ___________________________________________         Date: 
_______________  
Date of Birth: __________________________________ 
Your responses to this questionnaire are confidential.  If you answer “YES” to any of the 
following questions, please give additional details in the space provided and discuss the 
matter with one of the investigators.  You may refuse to answer any of the following 
questions. 
1. Have you ever had any major joint instability or ongoing chronic 
pain such as in the knee, back or elbow? 
YES NO 
2. Are you currently taking any medication (including aspirin) or have 
you taken any medication in the last two days? 
YES NO 
3. Have you taken any medication in the past six months? YES NO 
4. Is there any medical condition with which you have been diagnosed 
and are under the care of a physician (e.g. asthma, diabetes, 
anorexia)? 
YES NO 
5. Do you, or have you in the past, consumed any alcohol on a regular 
basis? 
YES NO 
6. Do you, or have you in the past, smoked on a regular basis? YES NO 
7. Are you, or have you in the past, engaged in any extreme diet? YES NO 
8. Have you had any fractures? YES NO 
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3.2 Godin Shephard Leisure Time Exercise Questionnaire 
GODIN-SHEPHARD LEISURE-TIME EXERCISE QUESTIONNAIRE 
 
 
1. Considering a 7-day period (a week), how many times on the average do you do the 
following kinds of exercise for more than 15 minutes during your free-time (write 
on each line the appropriate number)? 
  
           Times 
Per 
                   
Week 
 
(a) STRENUOUS EXERCISE 
(HEART BEATS RAPIDLY)                             
 _________ 
(i.e. running, jogging, hockey, football, soccer, squash, basketball,  
cross country skiing, judo, roller skating, vigorous swimming,  
vigorous long distance bicycling) 
 
(b) MODERATE EXERCISE       
 (NOT EXHAUSTING)      
 _________ 
(i.e. fast walking, baseball, tennis, easy bicycling, volleyball,  
badminton, easy swimming, alpine skiing, popular and folk dancing) 
 
(c) MILD EXERCISE 
 (MINIMAL EFFORT)      
 _________ 
 (i.e. yoga, archery, fishing from river bank, bowling, horseshoes,  
golf, snow-mobiling, easy walking) 
 
 
 
2. Considering a 7-day period (a week), during your leisure-time, how often do you 
engage in any regular activity long enough to work up a sweat (heart beats rapidly)?  
 
1. OFTEN    2. SOMETIMES  3. NEVER/RARELY 
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3.3 Food Frequency Questionnaire 
3.3.1 BLOCK Kids 
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3.3.2 Food and Activity Questionnaire 2004 
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3.4 Sexual Maturation 
Female Pubertal Stage 
 
FACULTY OF APPLIED HEALTH SCIENCES - BROCK UNIVERSITY 
 
 
 # 1: PLEASE LOOK AT BREAST SIZE ONLY                      
 
 
 
 
# 2: PLEASE LOOK AT PUBIC HAIR ONLY 
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Female Pubertal Stage 
 
FACULTY OF APPLIED HEALTH SCIENCES - BROCK UNIVERSITY 
 
 
 
 
NAME: _________________________________________________ 
 
 
 
This scale is to assess your maturational level. For both columns, please choose the 
appropriate stage and write the corresponding number on this piece of paper. 
 
 
 
Column #1: __________________ (corresponding number) 
 
 
Column #2: __________________ (corresponding number) 
 
 
 
Please answer the following questions: 
 
1. Have you had your period? 
 
YES   NO 
 
2. If yes, how old were you when you had your first period? ___________________ 
 
3. How often do you get periods? (in days)____________________________ 
 
4. For how many days does your period last? _______________________________ 
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Appendix 4: Data Collection Sheet 
ANTHROPOMETRIC MEASUREMENTS 
 
DOB:            
  
 
Height (cm): 
 
Seated Height (cm): 
Weight (kg): 
 
Age from PVH (years): 
BMI: 
 
% Body Fat: 
Hip Circumference (cm): 
 
Waist Circumference (cm): 
W:H Ratio: 
 
Tanner Stage: 
 
SPEED OF SOUND MEASUREMENTS 
RADIUS: 
TRIAL SOS T-SCORE Z-SCORE 
1    
2    
3    
 
TIME OF BLOOD DRAWS 
Draw 1 2 3 4 
Time 
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Appendix 5: Data Not Appearing in Main Body of Thesis 
5.1 Raw Data: Girls 
P
articip
an
t ID
 
A
ge (years) 
H
eigh
t (cm
) 
Seate
d
 H
eigh
t (cm
) 
A
ge fro
m
 p
eak 
h
eigh
t velo
city 
(years) 
W
eigh
t (kg) 
%
 B
F 
FFM
 (kg
) 
B
M
I 
W
aist 
C
ircu
m
feren
ce
 (cm
) 
H
ip
 C
ircu
m
feren
ce
 
(cm
) 
W
aist to
 H
ip
 R
atio
 
G0
2 8 
129.
6 66 -3 
27.4 
16.1 
22.9
9 16.2 53.5 70.3 
0.76 
G0
3 
8 
127.
8 67.5 -3.1 25.5 10.3 
22.8
7 15.6 51.5 65 0.79 
G0
4 
8 
132.
5 74 -2.9 26.7 6.1 
25.0
7 15 52 62 0.84 
G0
5 
12 
155.
2 76 0 41.9 22 
32.6
8 17.4 59 76 0.78 
G0
6 
12 159 78 0.3 46.2 17.4 
38.1
6 18.2 64.5 88.3 0.73 
G0
7 
10 138 68 -2.1 29.3 10.8 
26.1
4 15.4 53 72 0.74 
G0
8 
12 146 63 -0.8 33.6 15.8 
28.2
9 15.8 53 77 0.69 
G0
9 
9 144 74 -1.7 38.4 21.1 30.3 18.5 58 74.5 0.78 
G1
0 
9 
144.
6 70.5 -1.9 37.4 23.3 
28.6
9 17.9 63.5 76.8 0.83 
G1
1 
13 
159.
7 80.5 1.5 49.7 16.7 41.4 19.4 63.2 83 0.76 
G1
2 
12 
163.
6 81.7 1.1 58.4 25.8 
43.3
3 21.8 69 91 0.76 
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G1
3 
12 
149.
3 73.7 -0.4 
38.5
5   17.3    
G1
4 
11 149 72 -0.5 
38.5
5   17.4    
G1
5 
11 
141.
3 67.9 -1 
34.0
2   17    
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P
articip
an
t ID
 
Tan
n
er Stage
 
D
aily En
ergy 
In
take (kcal)  
D
aily C
alciu
m
 
In
take (m
g) 
M
ET
s p
er w
eek 
Scle
ro
stin
 A
 
(p
m
o
l/L) 
Scle
ro
stin
 B
 
(p
m
o
l/L) 
Scle
ro
stin
 C
 
(p
m
o
l/L) 
Scle
ro
stin
 D
 
(p
m
o
l/L) 
G02 
1 
1182.32 599.19 
63 
32.94 
18.62 16.48 32.91 
G03 
1 1462.57 568.6 90 26.35 13.73 24.24 20.59 
G04 
1 1567.24 1058.5 78    17.78 
G05 
3 1092.03 835.97 91 16.48 9.22 11.03 13.65 
G06 
3 1218.22 509.31 88   29.04 32.38 
G07 
1 1305.2 771.87 177 26.84 28.71 30.51 31.99 
G08 
2 1190.77 647.55 62 29.88 28.29 26 35 
G09 
1 1044.93 463.26 89 32.82 32.43 32.69 32.82 
G10 
1 630.93 523.61 162 36.7 35.55 36.48 37.31 
G11 
2 1191.16 492.97 148 27.9 26.71 26.05  
G12 
3 1231.61 403.8 66 42.77 43.6  34.28 
G13 
2 1303.23 393.96 109   37.2  
G14 
1 495.44 312.14 94 36.34 34.3   
G15 
1 1193.76 711.9 85 36.32 37.47 38.98  
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P
articip
an
t 
ID
 
D
K
K
-1 A
 
(p
m
o
l/L) 
D
K
K
-1 B
 
(p
m
o
l/L) 
D
K
K
-1 C
 
(p
m
o
l/L) 
D
K
K
-1 D
 
(p
m
o
l/L) 
O
P
G
 A
 
(p
m
o
l/L) 
O
P
G
 B
 
(p
m
o
l/L) 
O
P
G
 C
 
(p
m
o
l/L) 
O
P
G
 D
 
(p
m
o
l/L) 
G02 40.16 
20.9 9.49 38.31 6.96 3.31 2.59 6.43 
G03 
42.98 24.74 38.24 28.82 5.82 3.44 4.65 3.18 
G04 
   20.89    4.22 
G05 
36.84 25.56 25.19 30.19 3.82 2.57 2.85 3.74 
G06 
 22.39 24.1 24.57  8.1 11.15 12 
G07 
22.15 22.46 23.79 24.1 6.5 6.93 7.43 7.35 
G08 
20.98 21.45 19.73 23.79 6.15 6.2 6.1 7.4 
G09 
29.02 29.48 28.78 26.91 7.75 7.8 7.7 7.3 
G10 
26.25 25.82 25.74 25.9 13.78 13.5 13.65 13.75 
G11 
23.91 26.73 22.5  17.1 18.68 17.3  
G12 
31.36 33.48  25.74 16.6 17.1  14.15 
G13 
  31.22    18.98  
G14 
30.73 30.71   19.3 19.5   
G15 
31.82 35.06 33.11  17.1 19.5 19.25  
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P
articip
an
t 
ID
 
R
A
N
K
L A
 
(p
m
o
l/L) 
R
A
N
K
L B
 
(p
m
o
l/L) 
R
N
A
K
LC
 
(p
m
o
l/L) 
R
A
N
K
L D
 
(p
m
o
l/L) 
TG
F-β
1
 A
 
(n
g/m
l) 
TG
F-β
1
 B
 
(n
g/m
l) 
TG
F-β
1
 C
 
(n
g/m
l) 
TG
F-β
1
 D
 
(n
g/m
l) 
G02 2.37 
1.74 1.74 2.03 2.23 1.75 2.01 2.16 
G03 
 1.05  1.44 2.27 2.39 2.18 1.83 
G04 
   1.19 0  0 2.08 
G05 
2.18 2.61 2.18 1.74 2.14 2.63 2.18 2.06 
G06 
 1.6 1.6 2.45  0.67 0.68 1.05 
G07 
2.25 2.14 2.14 1.89 2.1 1.53 1.41 1.91 
G08 
2.39 2.39 0 2.39 2.53 1.8 1.86 1.74 
G09 
3.57 3.57 3.57 3.7 2.27 1.81 2.08 1.62 
G10 
2.8 2.02  2.5 1.41 1.12 1.21 1.09 
G11 
    0  0.58 0 
G12 
2.34 2.6  2.64 0.89 1.43 0 0.76 
G13 
  1.17  0  0.88 0 
G14 
1.95 1.64   1.02 1.05 0 0 
G15 
 1.55 1.17  2.12 2.13 2.35 0 
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P
articip
an
t 
ID
 
TG
F-β
2
 A
 
(p
m
o
l/L) 
TG
F-β
2
 B
 
(p
m
o
l/L) 
TG
F-β
2
 C
 
(P
m
o
l/L) 
TG
F-β
2
 D
 
(p
m
o
l/L) 
TG
F-β
3
 A
 
(n
g/m
l) 
TG
F-β
3
 B
 
(n
g/m
l) 
TG
F-β
3
 C
 
(n
g/m
l) 
TG
F-β
3
 D
 
(n
g/m
l) 
G02 0.16 
0.15 0.15 0.16 0.00488 0.00488 0.00528 0.00488 
G03 0.17 0.16 0.15 0.14 0.00488 0.00528 0.00488 0.00408 
G04    0.15    0.00488 
G05 0.15 0.18 0.15 0.14 0.00448 0.00528 0.00488 0.00488 
G06  0.08 0.09 0.13   0.00253 0.00253 
G07 0.17 0.14 0.14 0.17 0.00408 0.00369 0.00360 0.00408 
G08 0.18 0.15 0.15 0.15 0.00488 0.00448 0.00408 0.00448 
G09 0.2 0.17 0.18 0.15 0.00269 0.00251 0.00287 0.003486 
G10 0.14 0.13 0.12 0.12  0.00253  0.00253 
G11 0.19 0.19 0.19  0.00473 0.00473 0.00533  
G12 0.19 0.19 0.14 0.19 0.00473 0.00533 0.003609 0.00533 
G13   0.19    0.0059  
G14 0.19 0.19   0.00617 0.00533 0.002533  
G15 0.2 0.19 0.19  0.00533 0.0059 0.003609  
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5.2 Raw Data: Adolescents 
P
articip
an
t ID
 
A
ge (years) 
H
eigh
t (cm
) 
Seate
d
 H
eigh
t (cm
) 
A
ge fro
m
 p
eak 
h
eigh
t velo
city 
(cm
) 
W
eigh
t (kg) 
%
 B
F 
FFM
 (kg) 
B
M
I 
W
aist 
C
ircu
m
feren
ce
 
(cm
) 
H
ip
 C
ircu
m
feren
ce
 
(cm
) 
W
aist to
 H
ip
 R
atio
 
T0
1 14 
164.
7 83 1.7 46.1 12.3 
40.429
7 16.9 61 78.5 
0.7770700
64 
T0
2 
16 170 89 3.2 49 14.2 42.042 17 58 85.7 
0.6767794
63 
T0
3 
15 166 84.7 2.9 69.3 28.7 
49.410
9 24.8 75.5 100 0.755 
T0
4 
14 
160.
1 82 1.6 56.2 24.5 42.431 21.9 71.4 89.5 
0.7977653
63 
T0
5 
14 177 90 2.9 68.2 19.6 
54.832
8 21.9 70 95 
0.7368421
05 
T0
6 
13 
163.
1 87 1.8 53.7 20.1 
42.906
3 20.2 67 91.5 
0.7322404
37 
T0
7 
16 
148.
5 80 1.9 52.1 27.7 
37.668
3 23.6 67 91 
0.7362637
36 
T0
8 
15 165 79 2.5 67.4 33.1 
45.090
6 22.6 76.2 89.5 
0.8513966
48 
T0
9 
15 
170.
8 87.5 3.1 68.6 29.6 
48.294
4 23.5 77 94.5 
0.8148148
15 
T1
0 
16 157 83  63.9 36.5 
40.576
5 25.9 84 106 0.79 
T1
1 
16 154 84  67 36.8 42.344 28.3 85 108 0.79 
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T1
4 
16 
163.
7 85.5  57.3 21.1 
45.209
7 21.4 68 96 
0.7083333
33 
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P
articip
an
t 
ID
 
Tan
n
er 
M
ET
s p
er 
w
eek 
D
aily En
ergy 
In
take (kcal) 
D
aily 
C
alciu
m
 
In
take (m
g) 
S
clero
stin
 A
 
(p
m
o
l/L
) 
Scle
ro
stin
 B
 
(p
m
o
l/L) 
Scle
ro
stin
 C
 
(p
m
o
l/L) 
Scle
ro
stin
 D
 
(p
m
o
l/L) 
T01 5 64 1266.98 
1211.6 
 
30.58 33.264 29.084 
T02 
 60 1393.27 597.12 32.78 33.176 32.384 34.54 
T03 
5 55 1231.57 562.5 29.348 29.348 25.608 25.608 
T04 
4 117 1637.32 1752.99 30.976 33.792 33.264  
T05 
3 127 2500.28 1514.08 37.796 37.796 36.696 39.336 
T06 
3 88 1826.46 756.91 39.424 39.16 38.016 38.984 
T07 
4 116 2784.38 1206.96 34.98 34.848 35.156 33.814 
T08 
5 41 4105.75 2580.29     
T09 
3 126 3909.57 2370.25 30.052 29.48 31.24 27.808 
T10 
5 40   29.568 29.304 30.976 27.72 
T11 
5 22   32.736 31.152 26.532 31.416 
T14 
4 130 1428.39 934.43 28.732 28.468 28.468  
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P
articip
an
t 
ID
 
D
K
K
-1
 A
 
(p
m
o
l/L
) 
D
K
K
-1 B
 
(p
m
o
l/L) 
D
K
K
-1 C
 
(p
m
o
l/L) 
D
K
K
-1 D
 
(p
m
o
l/L) 
O
P
G
 A
 
(p
m
o
l/L
) 
O
P
G
 B
 
(p
m
o
l/L) 
O
P
G
 C
 
(p
m
o
l/L) 
O
P
G
 D
 
(p
m
o
l/L) 
T01  
25.194 27.3 24.492 
 
7.175 7.35 6.25 
T02 
17.94 18.096 17.94 18.096 6.35 6.25 6.5 6.15 
T03 
18.876 19.188 18.72 18.72 5.5 5.55 5.45 5.225 
T04 
23.868 25.584 25.038  7.45 11.825 9.125  
T05 
17.16 17.472 17.16 16.848 5.9 6 6.1 6.05 
T06 
18.408 18.408 18.564 18.408 6.8 6.9 6.9 7 
T07 
18.876 18.954 18.564 19.11 6 5.8 6.05 6 
T08 
27.456    6.75    
T09 
28.08 28.86 28.548 27.924 6.95 7 7 6.75 
T10 
26.13 26.13 23.673 25.662 11.3 11.15 8.15 10.325 
T11 
25.272 24.336 25.35 22.893 11.625 8.725 9.95 6.675 
T14 
31.434 31.8435 32.5065  16.725 17.1 18  
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P
articip
an
t 
ID
 
R
A
N
K
L
 A
 
(p
m
o
l/L
) 
R
A
N
K
L B
 
(p
m
o
l/L) 
R
A
N
K
L C
 
(p
m
o
l/L) 
R
A
N
K
L D
 
(p
m
o
l/L) 
T
G
F
-β
1
 A
 
(n
g/m
l) 
T
G
F
-β
1
 B
 
(n
g/m
l) 
T
G
F
-β
1
 C
 
(n
g/m
l) 
T
G
F
-β
1
 D
 
(n
g/m
l) 
T01  
1.4005 1.194 1.194 
 
1.682 1.4575 0.9455 
T02 
1.194 1.06 1.06 1.06 1.506 1.671 1.501 1.391 
T03 
2.198 1.6125 2.3485 1.902 1.629 1.935 2.008 2.023 
T04 
3.813 3.846 3.657  2.572 2.0215 1.947  
T05 
2.5 1.4705 1.194 1.756 1.5855 1.836 1.703 1.1525 
T06 
 1.6125 1.2625  1.0215 0.8855 1.161 1.015 
T07 
 1.2625  1.045 1.218 1.303 1.138 0.9965 
T08 
1.839    0.9305    
T09 
2.391 2.391 1.839 2.559 0.992 0.99 2.241 0.843 
T10 
3.625 3.675 2.725 3.625 0.9655 0.692 0.7715 1.027 
T11 
2.8 2.451 3.75 2.55 0.3665 0.52 0.677 0.712 
T14 
1.8085 1.3165 1.1735  0.41617 1.04042 1.53985 1.13335 
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P
articip
a
n
t ID
 
T
G
F
-β
2
 
A
 
(n
g/m
l) 
T
G
F
-β
2
 
B
 
(n
g/m
l) 
T
G
F
-β
2
 
C
 
(n
g/m
l) 
T
G
F
-β
2
 
D
 
(n
g/m
l) 
T
G
F
-β
3
 
A
 
(n
g/m
l) 
T
G
F
-β
3
 
B
 
(n
g/m
l) 
T
G
F
-β
3
 
C
 
(n
g/m
l) 
T
G
F
-β
3
 
D
 
(n
g/m
l) 
T01  
0.1135 0.109 0.1065  0.00253   
T02 
0.139 0.152 0.137 0.133 0.00235 0.00278 0.00235 0.00251 
T03 
0.13 0.15 0.15 0.153 0.00235 0.00235 0.00251 0.00234 
T04 
0.192 0.153 0.147 0 0.00251 0.00287   
T05 
0.1255 0.164 0.159 0.131 0.00234 0.00234 0.00253  
T06 
0.118 0.11 0.133 0.126 0.00253 0.00253 0.00253  
T07 
0.125 0.1245 0.1475 0.1045 0.00253 0.00358 0.00253  
T08 
0.10081 0.191 0.19 0.191     
T09 
0.09469 0.09631 0.1975 0.08449 0.00253 0.00253 0.00253  
T10 
0.085015 0.063 0.08441 0.08739 0.00167 0.00167 0.00212 0.00156 
T11 
0.05112 0.04912 0.04661 0.06935 0.00145 0.00145 0.00145 0.00167 
T14 
    0.00539 0.0059 0.0059  
 
